Back to GetFilings.com
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
[X ] ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT
OF 1934
For the fiscal year ended DECEMBER 31, 1999 Commission File Number: 000-23413
INTERLEUKIN GENETICS, INC.
(Name of Small Business Issuer in its Charter)
TEXAS 94-3123681
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
100 N.E. LOOP 410, SUITE 820
SAN ANTONIO, TEXAS 78216
(Address of principal executive offices)(Zip Code)
Issuer's Telephone Number: (210) 349-6400
Securities registered under Section 12(b) of the Exchange Act:
(Title of each class) (Name of each exchange on which registered)
COMMON STOCK, NO PAR VALUE BOSTON STOCK EXCHANGE
Securities registered under Section 12(g) of the Exchange Act:
(Title of each class)
COMMON STOCK, NO PAR VALUE
Check whether the issuer (1) filed all reports required to be filed by Section
13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter
period that the Registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days YES [X] NO [ ]
Check if there is no disclosure of delinquent filers in response to Item 405 of
Regulation S-K is not contained in this form, and no disclosure will be
contained, to the best of registrant's knowledge, in definitive proxy or
information statements incorporated by reference in Part III of this Form 10-K
or any amendment to this Form 10-K. [ ]
As of March 31, 2000, the aggregate market value of the Registrant's Common
Stock held by non-affiliates, based upon the average bid and asked price as of
such date, was $149,306,685. There were 17,988,686 shares of the Registrant's
Common Stock issued and outstanding as of March 31, 2000.
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the Registrant's Definitive Proxy Statement for the 2000
Annual Meeting of Shareholders to be held on June 5, 2000, are incorporated by
reference in Part III hereof.
ITEM 1. DESCRIPTION OF BUSINESS
CERTAIN STATEMENTS CONTAINED IN THIS FORM 10-K ARE "FORWARD-LOOKING
STATEMENTS" WITHIN THE MEANING OF THE SECTION 27A OF THE SECURITIES ACT OF 1933,
AS AMENDED AND SECTION 21E OF THE EXCHANGE ACT OF 1934, AS AMENDED.
SPECIFICALLY, ALL STATEMENTS OTHER THAN STATEMENTS OF HISTORICAL FACT INCLUDED
IN THIS FORM 10-K REGARDING THE COMPANY'S FINANCIAL POSITION, BUSINESS STRATEGY
AND PLANS AND OBJECTIVES OF MANAGEMENT OF THE COMPANY FOR FUTURE OPERATIONS ARE
FORWARD-LOOKING STATEMENTS. THESE FORWARD-LOOKING STATEMENTS ARE BASED ON THE
BELIEFS OF THE COMPANY'S MANAGEMENT, AS WELL AS ASSUMPTIONS MADE BY AND
INFORMATION CURRENTLY AVAILABLE TO THE COMPANY'S MANAGEMENT. WHEN USED IN THIS
REPORT, THE WORDS "ANTICIPATE," "BELIEVE," "ESTIMATE," "EXPECT" AND "INTEND" AND
WORDS OR PHRASES OF SIMILAR IMPORT, AS THEY RELATE TO THE COMPANY OR ITS
SUBSIDIARIES OR COMPANY MANAGEMENT, ARE INTENDED TO IDENTIFY FORWARD-LOOKING
STATEMENTS. SUCH STATEMENTS REFLECT THE CURRENT VIEW OF THE COMPANY WITH RESPECT
TO FUTURE EVENTS AND ARE SUBJECT TO CERTAIN RISKS, UNCERTAINTIES AND ASSUMPTIONS
RELATED TO CERTAIN FACTORS INCLUDING, WITHOUT LIMITATION, COMPETITIVE FACTORS,
GENERAL ECONOMIC CONDITIONS, CUSTOMER RELATIONS, RELATIONSHIPS WITH VENDORS, THE
INTEREST RATE ENVIRONMENT, GOVERNMENTAL REGULATION AND SUPERVISION, PRODUCT
INTRODUCTIONS AND ACCEPTANCE, TECHNOLOGICAL CHANGE, CHANGES IN INDUSTRY
PRACTICES, ONETIME EVENTS AND OTHER FACTORS DESCRIBED HEREIN AND IN THE
COMPANY'S REGISTRATION STATEMENT ON FORM S-3, AS AMENDED (FILE NO. 333-83631),
AND IN THE COMPANY'S ANNUAL, QUARTERLY AND OTHER REPORTS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION (COLLECTIVELY, "CAUTIONARY STATEMENTS").
ALTHOUGH THE COMPANY BELIEVES THAT ITS EXPECTATIONS ARE REASONABLE, IT CAN GIVE
NO ASSURANCE THAT SUCH EXPECTATIONS WILL PROVE TO BE CORRECT. BASED UPON
CHANGING CONDITIONS, SHOULD ANY ONE OR MORE OF THESE RISKS OR UNCERTAINTIES
MATERIALIZE, OR SHOULD ANY UNDERLYING ASSUMPTIONS PROVE INCORRECT, ACTUAL
RESULTS MAY VARY MATERIALLY FROM THOSE DESCRIBED HEREIN AS ANTICIPATED,
BELIEVED, ESTIMATED, EXPECTED, OR INTENDED. ALL SUBSEQUENT WRITTEN AND ORAL
FORWARD-LOOKING STATEMENTS ATTRIBUTABLE TO THE COMPANY OR PERSONS ACTING ON ITS
BEHALF ARE EXPRESSLY QUALIFIED IN THEIR ENTIRETY BY THE APPLICABLE CAUTIONARY
STATEMENTS. THE COMPANY DOES NOT INTEND TO UPDATE THESE FORWARD-LOOKING
STATEMENTS. PROSPECTIVE INVESTORS ARE ADVISED NOT TO RELY UPON FORWARD-LOOKING
STATEMENTS, BUT RATHER BASE THEIR INVESTMENT DECISION ON THE COMPANY'S ACTUAL
RESULTS TO DATE.
THE COMPANY
OVERVIEW
Interleukin Genetics, Inc., a Texas corporation ("ILGN" or the "Company"),
develops and commercializes genetic diagnostic tests and medical research tools.
The Company's efforts are focused on genetic factors that affect the rate of
progression of clinical disease through their influence on common host systems.
The Company's first genetic test, PST(R), a test predictive of risk for
periodontal disease, is currently marketed in the United States, Europe and
Israel. Products under development include tests predictive of risk for
osteoporosis, coronary artery disease, diabetic retinopathy, asthma, pulmonary
fibrosis and meningitis/sepsis. The Company believes by combining genetic risk
assessment with specific therapeutic strategies, improved clinical outcomes and
more cost-effective management of these common diseases may be achieved. ILGN
also develops and licenses its medical research tools, including BioFusion(R),
to pharmaceutical companies. BioFusion, a proprietary enabling system for
diagnostic and drug discovery and development, is a computer modeling system
that integrates genetic and other sub-cellular behavior, system functions, and
clinical symptoms to simulate complex diseases. This system allows useful
information to be derived from rapidly increasing databases of gene expression
being generated in companies and academic centers worldwide.
ILGN's executive offices are located at 100 N.E. Loop 410, Suite 820, San
Antonio, Texas 78216, and its telephone number is 210/349-6400. ILGN was
incorporated in Texas in 1986. ILGN maintains a website at www.ilgenetics.com.
In November 1997 ILGN completed an initial public offering of 1,800,000 shares
of common stock, no par value ("Common Stock"). In August 1999, the shareholders
of the Company approved the name change of the Company from Medical Science
Systems, Inc. to Interleukin Genetics, Inc.
-1-
Management believes the new name reflects the Company's focus on the interleukin
area of the human genome. On March 31, 2000, the closing bid price of the Common
Stock on the NASDAQ SmallCap Market was $10.06 per share.
CURRENT FINANCIAL CONDITION
Since its inception, the Company has incurred cumulative net losses of
approximately $21 million, including losses of approximately $6.1 million, $9.5
million and $4.5 million during 1999, 1998 and 1997, respectively. For the years
ended December 31, 1999, 1998, and 1997 the Company had negative cash flows from
operating activities of approximately $4.4 million, $8.5 million, and $3.4
million, respectively. As a result of these losses, available cash resources are
limited and will be depleted in September 2001 absent additional debt, equity
funding and/or growth in revenue.
In January 2000, the Company sold 832,667 shares of Common Stock in a
private placement. The Company received net proceeds of approximately $4.7
million from this private placement.
In June 1999, the Company completed a private placement of 2,200,000
shares of Series A Preferred Stock, no par value ("Series A Preferred"). The
Company received net proceeds of approximately $4.7 million from this private
placement. Following approval of this private placement by the Company's
shareholders on August 20, 1999, all of the issued and outstanding shares of
Series A Preferred converted into 11,000,000 shares of Common Stock.
STRATEGY
ILGN's objective is to be a leading genetics research and development
company focused on the discovery and development of diagnostic tests and medical
research tools. ILGN's strategy is to develop products for research and clinical
use that are commercialized through strategic collaborations. These products
include tests that are predictive of disease risk and tools for use in drug
development. The Company believes that it will, in the near term, generate
testing revenues, licensing fees, research and development funding, and
fee-for-service or participatory revenues pursuant to contracts with its
collaborative partners. In the long term, the Company believes it will generate
royalty payments from its corporate partners for new genetic tests and
therapeutic products. The Company believes that this strategy allows the Company
to generate near-term revenues and diversify risk, while building a proprietary
product portfolio with significant long-term potential. One of the Company's
core strengths is its ability to identify genetic variations or markers which
correlate with an individual's predisposition to a wide range of common chronic
diseases.
DEVELOPMENT SYSTEM AND APPROACH
Many factors, both environmental and genetic, contribute to most common
diseases. Importantly, some genetic factors are sufficiently strong that they
influence the onset and progression of a disease despite many other variables.
These genetic factors control aspects of the biology that have high leverage on
the disease. The Company has focused its research and product development
efforts on genetic factors that significantly influence the clinical course of
common, chronic diseases.
The Company's development program uses a proprietary enabling system
called BioFusion. BioFusion is a computer modeling system that integrates
genetic and other biological information to identify specific molecules or
biochemical pathways that have large magnitude effects on the progression of
disease and clinical outcomes. The Company then conducts clinical and basic
biological studies to test hypotheses generated by the modeling system.
-2-
Using this approach, the Company has demonstrated that certain genetic
factors are significant determinants of the clinical expression of multiple
common diseases. These factors affect the severity and the rate of progression
of clinical disease through their influence on host systems that are common to
several disease processes. A person who possesses the genetic marker (referred
to as a "genotype-positive individual) translates a disease challenge into a
higher clinical disease trajectory (more rapid progression of the disease) than
a genotype-negative individual with a comparable disease challenge.
PRODUCT PIPELINE AND PROPRIETARY POSITION
The Company has completed clinical trials and patent applications have
been filed or patents have been issued on the role of genetic factors in the
following diseases:
o Periodontitis (patent issued)
o Osteoporosis (patent issued)
o Coronary artery disease (patent pending)
o Diabetic retinopathy (patent pending)
o Meningitis/Sepsis (patent pending)
o Asthma (patent pending)
o Pulmonary Fibrosis (patent pending)
o Low Birth Weight (patent pending)
Based on these discoveries, the Company is developing a pipeline of tests
that are predictive of disease risk. Under development are tests predictive of
the disease risk for osteoporosis, coronary artery disease, diabetic retinopathy
(blindness associated with diabetes), asthma, pulmonary fibrosis and
meningitis/sepsis. PST, a test predictive of disease risk for periodontitis (gum
disease), was introduced commercially in the U.S. in the fourth quarter of 1997.
The Company considers several factors in determining whether to pursue new
genetic testing programs, including projected commercial potential,
effectiveness of current therapies and the status of competitive programs,
likelihood of attracting collaborators, and anticipated development costs.
In each clinical disease field, the Company's development program is
focused on understanding how genetic risk factors relate to overall risk for the
disease and establishing clear links to treatment. By combining genetic risk
assessment with specific therapeutic strategies, the Company believes improved
clinical outcomes and more cost-effective management of these common diseases
can be achieved. These genetic factors are also of value in both identifying
response patterns during clinical trials for the enhancement of existing
therapeutic agents and for developing new therapeutics directed at specific
immuno-inflammatory components of several common diseases.
CLINICAL UTILITY
The Company believes in the advantages a genetic approach to medicine
offers in the prevention, management and treatment of disease. The Company
believes its predictive tests and research tools are of value to:
o Pharmaceutical companies, who may use them to speed new drug development,
to improve the efficacy of their drugs, and to develop new therapeutics.
o Payors and organizations who provide health care services, who may use
them to stratify patients by risk and more effectively allocate resources
for the greatest benefit.
o Physicians and other healthcare professionals, who may use this
information to assess the risk involved for their patients and adopt
appropriate treatments or preventive strategies.
-3-
o Patients committed to staying healthy, who may use this information to
make better choices and set priorities based on personal knowledge of
their individual risk for common diseases.
TEST PREDICTIVE OF DISEASE RISK FOR PERIODONTAL DISEASE.
The Company's first genetic susceptibility test, PST, detects a genetic
susceptibility to severe gum disease (periodontitis). Periodontitis is a
bacterially-induced chronic inflammation that destroys the collagen fibers and
bone that surround and support the teeth. Untreated, periodontitis will
eventually result in tooth loss. Individuals who test positive for this genotype
will normally be placed on a more frequent recall program with their dental
provider, and would be candidates for more aggressive treatment.
The PST is the result of a scientific breakthrough in which an association
was discovered between a specific IL-1 genotype and severe periodontal disease.
IL-1 is a cytokine or protein that is known to play a role in inflammation and
the expression of periodontal disease. Patients with this specific genotype have
been found to progress more rapidly towards severe periodontal disease. It has
also been determined that cells with this genotype produce as much as four times
more IL-1 in response to the same bacterial challenge. Prevention or therapeutic
intervention aimed at reducing the bacterial challenge should decrease the
stimulus for IL-1 production and thereby protect the patient against the
potentially destructive effects of this genotype. It is estimated that
approximately 30% of the population will test positive for this genotype.
The Company has developed PST pursuant to a project agreement between the
Company and Sheffield University. In November, 1997, a patent related to the
detection of genetic predisposition to periodontal disease was issued to the
Company. The Company initiated commercial sales of PST in October 1997. In
December 1998, the Company entered into an agreement with Washington Dental
Service, a member of Delta Dental Plans Association, for the purchase of 1,200
PST tests to be used in a study sponsored by Washington Dental Service, in
collaboration with the University of Washington School of Dentistry and ILGN.
The study is designed to quantify the relationship between PST genotype status
and the utilization of dental services by patients in a dental plan.
The study, which began in early 1999, will provide scientific and
financial information about PST in a reimbursement system. If patients who are
at increased risk for periodontal disease can be identified early using PST,
services can be provided which should minimize the progression of disease and
the cost and complications of its consequences. The most costly dental
procedures are usually those associated with tooth loss due to advanced disease
(i.e., bridges, partial dentures, implants, etc.). Therefore, early
identification and intervention of high-risk patients is in the patients' and
payer's best interest. The Company believes that the results of this study will
provide important scientific and financial data regarding the use of PST as a
treatment- planning tool to assess risk before actual damage occurs. The data
from the study may be available for analysis in early 2001.
In September 1999, the Company introduced a saliva-based PST test which
replaces the Company's blood-based PST test.
The Company has entered into agreements for PST to be marketed in North
America, Europe and Israel.
TEST PREDICTIVE OF DISEASE RISK FOR OSTEOPOROSIS.
Osteoporosis, the most common bone disease, results in a decrease in the
amount of normal bone which leaves the affected individual more susceptible to
fractures. The Company has identified a genetic marker that in clinical trials
was associated with a more rapid loss of bone in women after menopause.
-4-
The clinical utility of the Company's osteoporosis susceptibility test
lies in its ability to predict a patient's future bone density trend. A genotype
positive test result is a significant risk factor for accelerated bone loss
after menopause. A positive patient is more likely to exhibit low bone mineral
density and experience severe fractures compared to a genotype negative patient.
Early patient identification and appropriate intervention can alter the rate of
the disease.
The Company's test provides data that will allow practitioners to practice
preventive medicine. Results of this test will assist women who are approaching
menopause in deciding whether to start treatment. This will enable counseling at
a sufficiently early stage in the process that significant bone loss can be
avoided through lifestyle modification and/or drug/hormone therapy.
During 1999, the Company completed a large scale clinical trial on its
osteoporosis test. The data from this trial confirms that the Company's genetic
factors are associated with an increase in risk of osteoporosis in
genotype-positive persons compared to genotype negative persons.
TEST PREDICTIVE OF DISEASE RISK FOR CORONARY ARTERY DISEASE (Patent Pending).
The Company's coronary artery disease test (the "CAD test") is a genetic
test capable of detecting those individuals with a significantly higher level of
susceptibility to coronary artery disease. This genetic marker can be combined
with other risk factors to identify individuals at high risk for developing a
more rapidly progressive and severe form of coronary artery disease.
The availability of the Company's CAD test will provide practitioners with
a means of truly practicing preventive medicine with respect to coronary artery
disease. The CAD test can be given to all individuals early in life because
genetic risk factors do not change over time. Individuals who test positive for
the genotype can be treated with more aggressive approaches to risk factor
reduction. As these individuals age, they can be provided with more regular: (i)
monitoring of cholesterol levels; (ii) blood pressure testing; and (iii) early
intervention to alter the level of blood lipids (I.E., fats). Such an approach
allows for truly preventive medicine through early risk factor reduction and
appropriate monitoring for early detection of any problems.
During 1999, the Company completed two large-scale clinical trials. The
data from these trials confirms that individuals with the IL-1 genetic marker
have an increased risk for heart disease even if such individuals do not have
high cholesterol. These findings are significant as over half of the first heart
attacks occur in individuals who cannot be identified using traditional risk
factors, such as smoking, high cholesterol, and diabetes. Genetic factors that
are independent of cholesterol may be of importance in identifying new
populations at increased risk for early heart disease. Once identified, these
individuals may reduce that risk by lowering cholesterol levels, even when the
cholesterol levels would not be considered "high" by currently accepted norms.
These factors may also provide new approaches to prevention and therapy.
TEST PREDICTIVE OF DISEASE RISK FOR RETINOPATHY IN DIABETICS (Patent Pending).
Another genetic susceptibility test, which is currently being developed by
the Company, is a test to determine the susceptibility to sight-threatening
retinopathy in diabetics. This susceptibility involves a continued and increased
risk of losing vision when an individual has been diagnosed with diabetes.
The Company has identified a genetic marker that is correlated with an
increased risk of developing diabetic retinopathy in patients who have diabetes.
This correlation seems to indicate an earlier onset of retinopathy in patients
who have diabetes thus putting such individuals at risk of losing their sight at
an earlier age. The availability of such a test would allow practitioners to
assess a patient's risk of losing his or her sight due to diabetes at the time
that he or she is diagnosed with the disease. Preventive treatment would allow
doctors to practice truly preventive medicine, providing a means of identifying
susceptible patients early in
-5-
the disease process. Enhanced assessment and monitoring can then be initiated
from the start, allowing early detection of problems and preemptive treatment
that will ultimately reduce the incidence of diabetes related vision loss. This
would translate into improvements in patient quality of life and cost savings.
To date, the Company has completed an initial study involving 500 patients who
demonstrated a strong association between specific genetic markers and
susceptibility to diabetic retinopathy.
TESTING PROCEDURE
Each of the Company's genetic susceptibility tests requires, or will
require, that a single procedure be utilized. To conduct a genetic
susceptibility test, the doctor draws a blood or saliva sample and submits it to
the Company's customer service department. The customer service department then
logs in the sample and submits sample batches to the ILGN laboratory or
reference lab for testing. The laboratory then performs the test following the
Company's specific protocol and informs the Company of the results. The Company,
in turn, advises the doctor of the results, who informs the patient and
determines the appropriate course of action. At the time results are provided to
the doctor, the Company's billing service will invoice the patient directly for
the test. The doctor will then invoice the patient for his or her professional
services related to administration of the test.
The Company will continue to use one or more sophisticated, certified, and
fully validated laboratories capable of providing consistent and high quality
analysis. Customer service is handled via the Company's toll free "888" numbers
by the Company's own staff who are knowledgeable about its genetic
susceptibility tests, the procedural requirements of the testing system and the
related diseases.
In the future, the Company may license the right to market and perform the
testing services to collaborative partners in exchange for a royalty or other
payments.
PRE-MARKETING TRIALS/STATUS OF PREDICTIVE TESTS
As an internal procedural standard, the Company conducts three categories
of clinical trials in conjunction with its genetic susceptibility tests. The
first trial is called a proof of principle trial, used to prove a laboratory
finding. The results of this trial are utilized to support the initial patent
application and therefore need to be completed before the patent application can
be filed. The second trial is a confirmatory trial. The purpose of the
confirmatory trial is to independently confirm the results of the proof of
principle trial. The third category of trial relates to clinical utility. The
clinical utility trial is conducted to learn what is the most effective
utilization of the test in actual clinical practice.
Following confirmatory studies, additional trials are completed on larger
populations to help develop broad scientific evidence supporting the clinical
utility of each of the Company's tests. Such additional trials not only
strengthen the support for each tests' known use (I.E., detecting genetic
susceptibility) but also lead to additional practical uses of the susceptibility
tests (E.G., use of the susceptibility tests to determine a patient's
responsiveness to a given drug).
PRODUCT DEVELOPMENT
The Company has ongoing research to continue to identify other genetic
factors that appear to be associated with other diseases. The Company plans on
filing additional patent applications to cover these discoveries. It is the
Company's intent to bring these discoveries to market in the form of tests
predictive of disease risk or medical research tools. The Company has also come
upon certain genetic factors that might be likely candidates to serve as
therapeutic targets, those susceptible to influence by drug agents. The Company
is considering certain collaborative long term relationships with pharmaceutical
companies as a
-6-
method to provide for either the licensing of its discoveries or to assist in
the research and development of future products.
STRATEGIC ALLIANCES AND COLLABORATIONS
The Company's strategy is to develop products for research and clinical
use and commercialize such products through strategic alliances. The Company has
followed a strategy of working with strategic partners at the fundamental
discovery stage. This strategy has given the Company access to discoveries while
reducing up-front research expenses.
SHEFFIELD UNIVERSITY
Since 1994, the Company has had a strategic alliance with the Department
of Molecular and Genetic Medicine at Sheffield University in the United Kingdom
("Sheffield"). Sheffield is a world leader in the genetic aspects of common
diseases with an inflammatory component. Under this alliance, Sheffield has
provided to the Company the fundamental discovery and genetic analysis from
Sheffield's research laboratories and the Company has focused on product
development, including clinical trials, and the commercialization of these
discoveries. See "Factors Affecting Future Performance - Reliance on
Collaborative Partners."
In October 1999 the Company entered into a new arrangement with Sheffield
and its investigators replacing the research and development agreement that had
been in place with Sheffield since 1996. Pursuant to this new arrangement, the
Company issued an aggregate of 475,000 shares of its Common Stock to Sheffield
and certain of its investigators in exchange for the relinquishment by Sheffield
of its net proceeds interests under certain agreements with the Company.
GLAXO WELLCOME
The Company has entered into a development and license agreement with
Glaxo Wellcome to develop a computer model in support of new compound screening.
ILGN's BioFusion proprietary technology provides a means of developing
computer-based simulation models of large, complex biological systems, which can
assist in the interpretation of gene expression and molecular screening
databases. The computer models can be used for a number of purposes, including
identifying new biologic targets for drug or diagnostic discovery, understanding
how genetic discoveries influence disease, and clinical trial design. The
Company has utilized this technology to support the development and
commercialization of its genetic tests and in support of drug development
efforts for large pharmaceutical companies.
DELTA DENTAL
The Company signed an agreement with Washington Dental Service, a member
of the Delta Dental Plans Association, for the purchase of 1,200 PST tests. PST
is the Company's test predictive of disease risk for periodontal disease (gum
disease). The tests will be used in a study, sponsored by Washington Dental
Service, in collaboration with the University of Washington School of Dentistry
and Medical Science Systems. The study is designed to quantify the relationship
between PST genotype status and the utilization of dental services by patients
in a dental plan.
The study, began in March 1999, is expected to provide scientific and
financial information about PST in a reimbursement system. This study is also
expected to provide scientific and financial data regarding the use of PST as a
treatment-planning tool to assess risk. The study is expected to be completed by
the end of 2000. See "Factors Affecting Future Performance - Reliance on
Collaborative Partners."
-7-
PST COMMERCIAL PARTNERSHIPS
In December 1997, the Company entered into an agreement with Medicadent, a
French corporation ("Medicadent"), to market and sell PST in France. In August
1998, the Company entered into an agreement with H.A. Systems, Ltd. to market
and sell PST in Israel. Medicadent commenced offering PST in France in June
1998, and H.A. Systems commenced offering PST in Israel in early 1999. In March
1999, the Company entered into an agreement with the Straumann Company to market
and sell PST in the United States and Puerto Rico. Straumann launched its PST
promotional activities in April 1999. In April 1999, the Company entered into an
agreement with Dumex, a subsidiary of AlPharma, a pharmaceutical manufacturer,
to market and sell PST in ten European countries (Austria, Denmark, Portugal,
Finland, Germany, Ireland, Norway, Sweden, Switzerland and the U.K.). Dumex is
well known in Europe as a manufacturer of oral health care products used by
periodontists. No assurances can be made regarding the commercial acceptance of
PST.
INTELLECTUAL PROPERTY
The Company's commercial success will be dependent in part on its ability
to obtain patent protection on genes, genetic sequences and/or their
relationship to common diseases, as well as diagnostic and therapeutic products
and methods based on the association between particular genes and diseases,
discovered by the Company and Sheffield University. The Company has a total of
four issued U.S. patents and 16 pending U.S. patent applications. Of the four
issued patents, two relate to the Company's genetic tests and two relate to
BioFusion, the Company's biologic modeling software. The U.S. Patent and
Trademark Office issued patents for the Company's periodontal and osteoporosis
tests in November and December, 1997, respectively.
The Company has been granted a number of corresponding foreign patents and
has filed foreign counterparts of its U.S. applications within the appropriate
time frames. Where the Company has originally filed in another country, it has
filed and plans to continue to file U.S. and other foreign counterparts within
the appropriate time frame. These applications seek to protect these gene
markers and corresponding use of gene markers, and products derived therefrom
and uses therefor.
The Company is continuing to identify and develop applications related to
additional genetic markers. The Company has also applied for trademark
protection for the name of its periodontal susceptibility test. The Company's
proprietary technology is subject to numerous risks. See "Factors Affecting
Future Performance."
COMPETITION
Competition in the Company's potential markets is intense. Although
testing for major genetic defects, such as Down's Syndrome, has been available
for years, genetic susceptibility testing for multi- factorial diseases is a
newly emerging growth segment. Despite this segment's relatively young age,
other companies do exist which have research programs seeking disease related
genes for therapeutic and susceptibility testing purposes, including some that
involve treatable/ preventable disease. The technologies for discovering genes
which predispose individuals to major diseases and approaches for
commercializing those discoveries are new and rapidly evolving. Rapid
technological developments could result in the Company's potential services,
products, or processes becoming obsolete before the Company recovers a
significant portion of its related research and development costs and capital
expenditures associated therewith.
Competitors of the Company in the United States and abroad are numerous
and include, among others, major pharmaceutical and diagnostic companies,
specialized biotechnology firms, universities and other research institutions,
including those receiving funding from the Human Genome Project. Other companies
with research programs include Myriad Genetics, Inc. ("Myriad") and Genome
Therapeutics Corp. ("GTC"). GTC has announced that it has research programs
focusing on osteoporosis. Myriad has a test for breast cancer
-8-
and has announced research programs for osteoporosis and coronary artery
disease. Many of the Company's other potential competitors have considerably
greater financial, technical, marketing and other resources than the Company,
which may allow these competitors to discover important genes in advance of the
Company. If the Company does not discover disease-predisposing genes,
characterize their functions, develop genetic tests and related information
services based on such discoveries, obtain regulatory and other approvals, and
launch such services or products before competitors, the Company could be
adversely affected.
Additionally, some of the Company's competitors receive data and funding
from the Human Genome Project. The Human Genome Program is a federally funded
program focused on sequencing the human DNA and enriching the sequence data with
information about its biological function. To the extent the Company's
competitors receive data and funding from the Human Genome Project at no cost to
them, they may have a competitive advantage over the Company.
In the case of newly introduced products requiring "change of behavior,"
(such as genetic susceptibility tests) multiple competitors may accelerate
market acceptance and penetration through increasing awareness. Moreover, two
different genetic susceptibility tests for the same disease may in fact test or
measure different components, and thus actually be complementary when given in
parallel as an overall assessment of risk, rather than being competitive with
each other.
Furthermore, the primary focus of each of the above-referenced companies
is performing gene- identifying research for pharmaceutical companies for
therapeutic purposes, with genetic susceptibility testing being a secondary
goal. On the other hand, the Company's primary business focus is developing and
commercializing genetic susceptibility tests for common diseases, with only an
ancillary drug discovery program.
GOVERNMENT REGULATION
The sampling of blood, saliva or cheek scrapings from patients and
subsequent analysis in a clinical laboratory does not, at the present time,
require Federal Drug Administration ("FDA") or regulatory authority approval
inside the U.S. for either the sampling procedure or the analysis itself. The
samples are taken in the healthcare provider's office, using standard materials
previously approved as medical devices, such as sterile lancets and swabs. The
testing procedure itself is performed in one or more registered, certified
clinical laboratories under the auspices of the Clinical Laboratory Improvement
Act of 1988 ("CLIA"), administered by the Health Care Financing Administration.
The federal regulations governing approval of the laboratory facilities and
applicable state and local regulations governing the operation of clinical
laboratories would also apply to the laboratories performing tests for the
Company. Changes in such regulatory schemes could require advance regulatory
approval of genetic susceptibility tests sometime in the future and could have a
material adverse effect on the Company's business. In addition, certain billing
practices of the Company required it, or a subsidiary, to be licensed and
regulated under CLIA.
In addition, while the Company's main focus is on genetic susceptibility
testing, the Company may, in the future, endeavor to partner with pharmaceutical
companies in the area of drug development. Any drug products developed by the
Company or the Company's future collaborative partners, prior to marketing in
the United States, would be required to undergo an extensive regulatory approval
process by the FDA. The regulatory process, which includes preclinical testing
and clinical trials of each therapeutic product in order to establish its safety
and efficacy, can take many years and requires the expenditure of substantial
resources. Data obtained from preclinical and clinical activities are
susceptible to varying interpretations which could delay, limit or prevent
regulatory agency approval. In addition, delays or rejections may be encountered
during the period of therapeutic development, including delays during the period
of review of any application. Delays in obtaining regulatory approvals could
adversely affect the marketing of any therapeutics developed by the Company or
its collaborative partners, impose costly procedures upon the Company and its
collaborative
-9-
partners' activities, diminish any competitive advantages that the Company or
its collaborative partners may attain and adversely affect its ability to
receive royalties. Once regulatory approval of a product is granted, such
approval may impose limitations on the indicated uses for which it may be
marketed. Further, even if such regulatory approval is obtained, a marketed
product and its manufacturer are subject to continuing review. The discovery of
previously unknown problems with a product or manufacturer may result in
restrictions on such product or manufacturer. Such restriction could include
withdrawal of the product from the market.
EMPLOYEES
As of March 31, 2000, the Company had 13 full-time employees. Of the
Company's employees, 77% are engaged directly in the development and
commercialization of tests and 23% are engaged in administrative or managerial
activities.
The Company's employees are not covered by a collective bargaining
agreement, and the Company considers its relations with its employees to be
good.
FACTORS AFFECTING FUTURE PERFORMANCE
NO ASSURANCE OF ADDITIONAL NECESSARY CAPITAL
The Company anticipates that its current financial resources will be
adequate to maintain its current and planned operations through September 2001.
THERE CAN BE NO ASSURANCE THAT THE COMPANY WILL BE ABLE TO RAISE ANY ADDITIONAL
NECESSARY CAPITAL. IF ADDITIONAL AMOUNTS CANNOT BE RAISED, THE COMPANY WOULD
SUFFER MATERIAL ADVERSE CONSEQUENCES TO ITS BUSINESS, FINANCIAL CONDITION AND
RESULTS OF OPERATIONS AND WOULD LIKELY BE REQUIRED TO SEEK PROTECTION UNDER THE
UNITED STATES BANKRUPTCY LAWS.
The Company's future capital requirements will depend on many factors,
including successful expansion of sales of PST(R), the Company's genetic test
for periodontal disease, and continued scientific progress with its research and
development programs. The continuation of the Company's research and development
activities may require substantial additional capital from private or public
sources. There is no assurance that such capital will be available to the
Company on acceptable terms. Furthermore, the market for publicly-traded stocks
of biotechnology companies has historically been volatile, and the competition
for equity capital from public and private sources is intense among the over
1,000 biotechnology companies in the United States that are dependent on
infusions of capital to fund their operations. The Company is also engaged from
time to time in discussions with several companies concerning the licensing of
certain of the Company's proprietary technologies or forming strategic
alliances, which could provide additional sources of funding to the Company as
well as a possible source of equity capital. The Company is unable to predict
the likelihood of completing any such arrangements. There can be no assurance
that the Company will be successful in obtaining additional capital in amounts
sufficient to continue to fund its operations and product development.
INABILITY TO FULLY USE NET OPERATING LOSS CARRYFORWARDS
As of December 31, 1999, and 1998 the Company had net operating loss
carryforwards and a research tax credit of approximately $18,750,000 and
$187,000, respectively, for federal income tax purposes, expiring in varying
amounts through the year 2019. The Company's ability to use its NOL and credit
carryforwards to reduce future taxes is subject to Section 382 of the Internal
Revenue Code of 1986 (the "Code"). These restrictions provide for limitations on
the Company's utilization of its NOL and credit carryforwards following a
greater than 50% ownership change during the prescribed testing period. As of
December 31, 1999, the Company had incurred such a change. As a result,
approximately $15,619,000 of the Company's NOL
-10-
carryforwards are limited in utilization to approximately $825,000 annually. The
annual limitation may result in the expiration of the carryforwards prior to
utilization.
UNCERTAINTY OF MARKET ACCEPTANCE FOR GENETIC SUSCEPTIBILITY TESTS
The commercial success of the Company's genetic susceptibility tests and
those that it may develop will depend upon their acceptance as medically useful
and cost-effective by patients, physicians, dentists, other members of the
medical and dental community and insurers. Broad market acceptance can be
achieved only with substantial education about the benefits and limitations of
such tests. It is uncertain whether current genetic susceptibility tests or
others that the Company may develop will gain market acceptance on a timely
basis. If patients, dentists and physicians do not accept the Company's tests,
or take a longer time to accept than the Company anticipates, then the Company's
revenues and profit margins may be reduced and may result in losses.
DIFFICULTY OF DEVELOPING GENETIC SUSCEPTIBILITY TESTS
It is uncertain whether the Company will be successful in developing and
bringing to market its current portfolio or future tests based on the genetic
discoveries made by the Company and its collaborators. Even when the Company
discovers a genetic marker (I.E., a genetic variation or polymorphism associated
with increased disease incidence or severity), additional clinical trials need
to be conducted to confirm the initial scientific discovery and to support the
scientific discovery's clinical utility in the marketplace. The results of a
clinical trial could delay, reduce the test's acceptance or cause the Company to
cancel a program. Such delays, reduced acceptance or cancellations would reduce
revenues and may result in losses.
HISTORY OF OPERATING LOSSES; ACCUMULATED DEFICIT; UNCERTAINTY OF FUTURE
PROFITABILITY
The Company incurred a net operating loss of $6,138,603 in 1999,
$9,508,275 in 1998 and $4,494,062 in fiscal year 1997. As of December 31, 1999,
our accumulated deficit was $21,012,188. The losses have resulted principally
from expenses incurred in research and development and from selling, general and
administrative expenses. These expenses have exceeded revenues. The Company has
yet to generate any significant revenues from the sale of genetic susceptibility
testing services and there can be no assurance that it will be able to generate
significant revenues in the future. The Company expects operating losses to
continue for the near future as research and development, sales and marketing
activities and operations continue. The ability to achieve profitability depends
on the ability to develop a sales and marketing capacity and to successfully
market and sell products and services. It is uncertain when the Company will
become profitable.
UNCERTAINTY OF INSURANCE REIMBURSEMENT
The Company's ability to successfully commercialize existing genetic
susceptibility tests and others that the Company may develop depends in part on
obtaining adequate reimbursement for such testing services and related
treatments from government and private health care insurers (including health
maintenance organizations) and other third-party payors. Physicians' and
dentists' decisions to recommend genetic susceptibility tests, as well as
patients' elections to pursue testing, are likely to be heavily influenced by
the scope and extent of reimbursement for such tests by third-party payors.
Government and private third-party payors are increasingly attempting to contain
health care costs by limiting both the extent of coverage and the reimbursement
rate for new testing and treatment products and services. In particular,
services which are determined to be investigational in nature or which are not
considered "reasonable and necessary" for diagnosis or treatment may be denied
reimbursement coverage. To date, few insurers or third-party payors have agreed
to reimburse patients for genetic susceptibility tests. As a result, the Company
initially expects to bill patients directly for the genetic susceptibility
tests.
-11-
It remains uncertain whether insurers or third-party payors will elect to
provide full reimbursement coverage for the genetic susceptibility tests in the
near future. If adequate reimbursement coverage is not available from insurers
or third-party payors, it is uncertain whether individuals will elect to
directly pay for the test. If both insurers or third-party payors and
individuals are unwilling to pay for the test, then the number of tests
performed will be significantly decreased. Such a scenario would result in
reduced revenues and possible losses.
RELIANCE ON COLLABORATIVE PARTNERS
In October 1999, the Company entered into a new contractual arrangement
with the University of Sheffield ("Sheffield") replacing the research and
development agreement that had been in place since 1996. Under this new
arrangement, the Company will undertake the development and commercialization of
certain discoveries resulting from Sheffield's research. This agreement with
Sheffield has a five-year term with an automatic yearly renewal. Pursuant to
this new arrangement, the Company issued an aggregate of 475,000 shares of its
Common Stock to Sheffield and its investigators in exchange for the transfer of
certain patent rights and the relinquishment of proceeds interests held by
Sheffield and its investigators under all project agreements. The Company also
entered into a research and development services agreement with Sheffield which
automatically renews in one-year increments. In connection with this new
arrangement, the Company entered into a five-year consulting agreement with
Sheffield's key collaborator. The Company anticipates entering into additional
collaborative arrangements with Sheffield and other parties in the future.
In the future the Company may, in order to facilitate the sale of testing
services and/or products, enter into collaborative selling arrangements with one
or more other persons. It is uncertain whether the Company will be able to
negotiate acceptable collaborative arrangements in the future or that such
collaborative arrangements will be successful. If the Company is unable to
identify collaborative partners to sell certain of our services and/or products,
it may be forced to develop an internal sales force to market and sell its
services and/or products in markets where it is not intending on developing a
direct selling presence. Such a process would take more time and potentially
cost more. As a result, revenues and earnings would be reduced. If the Company
enters into collaborative selling arrangements, its success will depend upon the
efforts of others and may be beyond its control. Failure of any collaborative
selling arrangement could result in reduced revenues and possible losses.
UNCERTAIN ABILITY TO PROTECT PROPRIETARY TECHNOLOGY
The Company's success will partly depend on its ability to obtain patent
protection, both in the United States and in other countries, for its products
and services. In addition, the Company's success will also depend upon its
ability to preserve its trade secrets and to operate without infringing the
proprietary rights of third parties.
The Company has sixteen (16) patent applications pending, including
applications covering certain of its anticipated genetic susceptibility tests.
There can be no assurance that the Company's patent applications will ever be
issued as patents or that the claims of any issued patents will afford
meaningful protection for the Company's technology or products. Further, others
may develop similar products which test for susceptibility related to some
diseases yet avoid infringing upon, or conflicting with, the Company's
anticipated patents. In addition, there can be no assurance that any patents
issued to the Company will not be challenged, and subsequently narrowed,
invalidated or circumvented.
The Company's testing services and/or products may also conflict with
patents which have been or may be granted to others. As the biotechnology
industry expands and more patents are filed and issued, the risk increases that
the Company's products may give rise to a declaration of interference by the
Patent and Trademark Office, or to claims of patent infringement by other
companies, institutions or individuals. Such
-12-
entities or persons could bring legal proceedings against the Company seeking
damages or seeking to enjoin the Company from testing, manufacturing or
marketing its products. Patent litigation is costly, and even if the Company
prevails, the cost of such litigation could have an adverse effect on the
Company. If the other parties in any such actions are successful, in addition to
any liability for damages, the Company could be required to cease the infringing
activity or obtain a license. It is uncertain whether any license required would
be available to the Company on acceptable terms, if at all. Failure by the
Company to obtain a license to any technology that it may require to
commercialize its products could have a material adverse effect on the Company's
business, financial condition, results of operations and cash flows. In
addition, there is considerable pressure on academic institutions and other
entities to publish discoveries in the genetic field. Such a publication by an
academic institution or other entity, prior to the Company's filing of a patent
application on such discovery, may compromise the Company's ability to obtain
U.S. and foreign patent protection for the discovery.
The Company also relies upon unpatented proprietary technologies. The
Company relies on confidentiality agreements with its employees, consultants and
collaborative partners to protect such proprietary technology. There can be no
assurance that the Company can adequately protect its rights in such unpatented
proprietary technologies, that others will not independently develop
substantially equivalent proprietary information or techniques, or otherwise
gain access to the Company's proprietary technologies or disclose such
technologies.
The United States Patent and Trademark Office issued new Utility
Guidelines in July 1995 that address the requirements for demonstrating utility,
particularly in inventions relating to human therapeutics. While the guidelines
do not require clinical efficacy data for issuance of patents for human
therapeutics, there can be no assurance that the Patent and Trademark Office's
interpretations of such guidelines, and any changes to such interpretations will
not delay or adversely affect the Company's or the Company's collaborators'
ability to obtain patent protection. The biotechnology patent situation outside
the United States is even more uncertain and is currently undergoing review and
revision in many countries.
TECHNOLOGICAL CHANGES RESULTING IN PRODUCT OBSOLESCENCE
Market acceptance and sales of the Company's testing services could also
be adversely affected by technological change. It is uncertain whether the
Company's competitors will succeed in developing genetic susceptibility tests
that circumvent or are more effective than the Company's technologies or
services. Further, it is uncertain whether such developments would render the
Company's or the Company's collaborators' technology or services less
competitive or obsolete. Further, the Company's testing services could be
rendered obsolete as a result of future innovations in the treatment of gum
disease, osteoporosis, coronary artery disease or diabetes retinopathy, which
could have a significant negative impact on the Company's ability to market its
services effectively.
POSSIBLE NASDAQ DELISTING; LIMITED PUBLIC MARKET FOR COMMON STOCK;
POSSIBLE VOLATILITY OF SECURITIES PRICES
Our Common Stock is currently listed on The NASDAQ SmallCap Market and the
Boston Stock Exchange. If the Company fails to maintain the qualification for
its Common Stock to trade on the NASDAQ SmallCap Market or the Boston Stock
Exchange, its Common Stock could be subject to delisting. The NASDAQ Stock
Market, Inc. ("NASDAQ") announced increases in the quantitative standards, which
became effective in February 1998, for maintenance of any of (x) $2,000,000 of
net tangible assets, (y) $35,000,000 of market capitalization or (z) $500,000 of
net income for two of the last three years and a minimum bid price per share of
$1.00. On February 3, 1999, we received notice from NASDAQ that we were in
violation of NASDAQ's minimum bid price requirement and that if our Common Stock
does not have a closing bid price of at least $1.00 for ten consecutive trading
days during the 90 day period ended May 3, 1999, our Common Stock will be
subject to delisting on May 3, 1999. The Company believes it has satisfied this
requirement by
-13-
having a closing bid price of at least $1.00 for each trading day since May 7,
1999; however the Company has not received notice from NASDAQ that such
requirement was satisfied. Furthermore, there can be no assurance that our stock
price will maintain such $1.00 minimum bid price. If the market price for our
Common Stock does fall below the $1.00 bid price, our Common Stock could be
subject to delisting from The NASDAQ SmallCap Market.
On April 19, 1999, the Company received notice from the NASDAQ SmallCap
Market that the Company was in violation of NASDAQ's $2,000,000 minimum net
tangible asset requirement. As a result of the private placement completed in
June 1999, management believes that the Company is in compliance with NASDAQ's
minimum net tangible asset requirement; however, the Company has not received
notice from NASDAQ that such requirement was satisfied. The Company filed a
Current Report on Form 8-K dated June 25, 1999, containing the Company's pro
forma balance sheet at May 31, 1999, adjusted to reflect the results of the June
private placement. Such balance sheet reflects net tangible assets in excess of
$2,000,000. If the Company is unable to maintain compliance with NASDAQ's
minimum net tangible asset requirement, or maintain a $35,000,000 market
capitalization, the Company would likely be delisted from the NASDAQ SmallCap
Market and may also suffer material adverse consequences to its business,
financial condition and results of operations.
On August 3, 1999, the Company received a notice from NASDAQ questioning
whether the Company had violated the shareholder approval provisions of the
NASDAQ Marketplace Rules due to an alleged change- in-control resulting from the
private placement of Series A Preferred Stock completed by the Company in June
1999. As a result, NASDAQ is reviewing the Company's eligibility for continued
listing on the NASDAQ SmallCap Market. The Company does not believe that a
change-of-control occurred and is engaged in discussions with NASDAQ to resolve
this matter; however, as of March 1, 2000, the Company had not received
notification of NASDAQ's decision regarding this matter. At the Annual Meeting
held August 20, 1999, our shareholders ratified the private placement of Series
A Preferred Stock. There can be no assurance that the Company will be able to
address this issue in a manner satisfactory to NASDAQ, or that the Company's
Common Stock will not be delisted from the NASDAQ SmallCap Market.
If our shares are not listed as intended, trading, if any, would be
conducted in the over-the-counter market in the so-called "pink sheets" or the
OTC Bulletin Board, which was established for securities that do not meet the
NASDAQ SmallCap Markets listing requirements. Consequently, selling our shares
would be more difficult because smaller quantities of shares could be bought and
sold, transactions could be delayed, and security analysts' and news media's
coverage of our company may be reduced. These factors could result in lower
prices and larger spreads in the bid and ask prices for our share.
If our shares are not listed on the NASDAQ SmallCap Market and/or the
Boston Stock Exchange, they may become subject to Rule 15g-9 under the Exchange
Act. That rule imposes additional sales practice requirements on broker-dealers
that sell low-priced securities to persons other than established customers and
institutional accredited investors. For transactions covered by this rule, a
broker-dealer must make a special suitability determination for the purchaser
and have received the purchaser's written consent to the transaction prior to
sale. Consequently, the rule may affect the ability of broker-dealers to sell
our shares and affect the ability of holders to sell our shares in the secondary
market.
The SEC's regulations define a "penny stock" to be any equity security
that has a market price less than $5.00 per share or with an exercise price of
less than $5.00 per share, subject to certain exceptions. The penny stock
restrictions will not apply to our shares if they are listed on the NASDAQ
SmallCap Market or the Boston Stock Exchange and we provide certain price and
volume information on a current and continuing basis, or meet required minimum
net tangible assets or average revenue criteria. We cannot assure you that our
shares will qualify for exemption from these restrictions. If our shares were
subject to the penny stock rules, the market liquidity for the shares could be
adversely affected.
-14-
Historically, the Common Stock has experienced low trading volumes. The
market price of the Common Stock also has been highly volatile and it may
continue to be highly volatile as has been the case with the securities of other
public biotechnology companies. Factors such as announcements by the Company or
its competitors concerning technological innovations, new commercial products or
procedures, proposed government regulations and developments or disputes
relating to patents or proprietary rights may substantially affect the market
price of the Company's securities. Changes in the market price of the Common
Stock may bear no relation to the Company's actual operational or financial
results.
LIMITED MARKETING OR SALES EXPERIENCE
Our business strategy is to provide genetic susceptibility testing
services aimed at common diseases that are treatable and preventable. The
commercial introduction of the periodontal susceptibility test at the beginning
of October 1997 represented our first such effort. From its commercial inception
through 1999, our periodontal susceptibility test has generated revenues of
$866,726. With respect to the periodontal susceptibility test, we have devoted
substantial human and financial resources to the establishment and staffing of a
customer service support facility and the building of a sales and marketing
infrastructure. However, we have limited experience in developing and
commercially marketing susceptibility testing services. It is uncertain whether
our customer service support facilities and sales and marketing program will
achieve efficient, effective or successful operations. Failure to successfully
market such tests could reduce our revenues and may result in losses.
PRODUCT LIABILITY EXPOSURE
Our business exposes us to potential liability risks inherent in the
testing and marketing of medical and dental related services or products. It is
uncertain whether liability claims will be asserted against us. We have product
and professional liability insurance which we believe provides coverage for the
testing and commercial introduction of our genetic susceptibility tests. It is
uncertain whether we will be able to maintain such insurance on acceptable
terms. Any insurance obtained may not provide adequate coverage against
potential liabilities. A liability claim, even one without merit, could result
in significant legal defense costs thereby increasing our expenses, lowering our
earnings and even resulting in losses.
ETHICAL, LEGAL AND SOCIAL IMPLICATIONS OF GENETIC TESTING
The prospect of broadly available genetic testing has raised issues which
are currently being widely discussed by the medical and scientific communities,
as well as other interested groups and organizations, regarding the appropriate
utilization and the confidentiality of information provided by such testing. The
recent movement towards discovery and commercialization of susceptibility tests
for assessing a person's likelihood of developing a chronic disease has also
focused public and legislative attention on the need to protect the privacy of
genetic assessment medical information. With the progression towards more
comprehensive record keeping by health insurers and managed care firms, this
need has led to a number of legal initiatives. The recently enacted federal
health insurance reform law (Health Insurance Portability Act of 1996)
recognizes the comparability of information obtained by genetic means to other
types of personal medical information. The law prohibits insurance companies
from refusing health insurance coverage to individuals on the basis of their
medical history, including "genetic information." This legislation also
prohibits employees from discrimination in hiring practices on the same basis.
This legislation indicates a trend to protect the privacy of patients while
allowing them to be screened for conditions which, can be prevented, reduced in
severity or cured. In the most extreme scenario, governmental authorities could,
for social or other purposes, limit the use of genetic testing or prohibit
testing for genetic susceptibility to certain conditions. For these reasons, we
could experience a delay or reduction in test acceptance. Such a delay or
reduction could reduce our revenues or result in losses.
-15-
We are taking a proactive stance in the ethical arena. Our Chief Executive
Officer, Dr. Philip Reilly, is both an M.D. (certified specialist in clinical
genetics) and an attorney and is knowledgeable in the area of genetic testing
and its ethical, legal and clinical utility ramifications. Additionally, we are
currently advising doctors who administer our genetic susceptibility tests to
take special efforts to maintain the confidentiality of the test results. Our
intent is to avoid information about test results being disclosed to insurers
until issues regarding insurability have been fully analyzed and acted upon by
the appropriate legislative bodies.
DEPENDENCE ON KEY PERSONNEL AND CONSULTANTS
Because of the specialized scientific nature of our business, we are
highly dependent upon our ability to attract and retain qualified management,
scientific and technical personnel. Our company will also be dependent upon the
ability to hire qualified marketing and sales personnel. Competition for
scientific, marketing and sales personnel is intense. Loss of the services of
Drs. Kornman or Reilly or Gordon Duff, a key researcher with the University of
Sheffield, could adversely affect our research and development programs and
susceptibility testing service business and could impede the achievement of our
business objectives. We maintain key man life insurance on Drs. Kornman and
Duff.
ABSENCE OF DIVIDENDS
We have never paid dividends and do not intend to pay any dividends in the
foreseeable future.
SHARES ELIGIBLE FOR FUTURE SALE
Substantially all of the outstanding Common Stock is available for sale in
the public marketplace. There are also outstanding stock options and warrants to
purchase an aggregate of 3,258,675 shares of Common Stock at various exercise
prices per share. No prediction can be made as to the effect, if any, that sales
of shares of Common Stock or the availability of such shares for sale will have
on the market prices prevailing from time to time. The possibility that
substantial amounts of Common Stock may be sold in the public market may
adversely affect prevailing market prices for the Common Stock, and could impair
the Company's ability to raise capital through the sale of its equity
securities.
EFFECT OF PREFERRED STOCK AND DIRECTOR REMOVAL PROVISIONS
Our Board of Directors is authorized to issue up to 5,000,000 shares of
Preferred Stock and to determine the price, rights, preferences and privileges
of those shares without any further vote or action by our shareholders. The
rights of the holders of Common Stock will be subject to, and may be adversely
affected by, the rights of the holders of any shares of Preferred Stock that may
be issued in the future. While we have no present intention to issue shares of
Preferred Stock, such issuance, while providing desirable flexibility in
connection with possible acquisitions and other corporate purposes, could have
the effect of making it more difficult for a third party to acquire a majority
of our outstanding voting stock. In addition, such Preferred Stock may have
other rights, including economic rights, senior to the Common Stock. As a
result, the issuance of Preferred Stock could decrease the market value of the
Common Stock.
Our Articles of Incorporation provide that members of the Board of
Directors may be removed only for cause upon the affirmative vote of holders of
at least a majority of the shares of our outstanding capital stock entitled to
vote. Certain other provisions of our Articles of Incorporation could also have
the effect of delaying or preventing changes of control or in management. Such a
delay or preventive effect could adversely affect the price of our Common Stock.
-16-
ITEM 2. PROPERTIES
The Company has two offices in the following locations: Flagstaff, Arizona
and San Antonio, Texas. Flagstaff, Arizona is the site of the Company's global
commercial operations, including its marketing, sales and customer service
organization. The San Antonio Research Center is the principal site of its
research and development and employs teams of top medical, dental and computer
scientists. San Antonio is the site of its corporate headquarters.
The Company's commercial operations office located at 3100 N. West Street,
Bldg. A, Flagstaff, Arizona, contains 6,000 square feet and is held under a five
year lease which expires in September 2002. The Company's corporate headquarters
and research and development offices, located at 100 N.E. Loop 410, Suite 820,
San Antonio, Texas, contain 8,131 usable square feet held under a lease expiring
May 31, 2003. The Company's former corporate headquarters, located at 4400
MacArthur Boulevard, Suite 980, Newport Beach, California, contains 1,798 usable
square feet and has been subleased by the Company until the expiration of the
Company's original lease in April 2001.
ITEM 3. LEGAL PROCEEDINGS
On March 2, 1999, Entelos, Inc. filed an action against the Company in
United States District Court for the Northern District of California, alleging
that two of Entelos' principals, Samuel Holtzman and Thomas Paterson, are
co-inventors of the inventions claimed in two of the Company's patents - U.S.
Pat. Nos. 5,657,255 and 5,808,918, both of which relate to the Company's
BioFusion products. In the suit, Entelos seeks a declaratory judgment that
Entelos is the co-owner of all rights under the foregoing patents, an order
correcting the inventorship of the patents to list Holtzman and Paterson as
co-inventors, and restitution to Entelos of its share of the profits obtained
from the patents. The complaint also asserted an unfair competition claim. In
June 1999 the Company entered into a settlement agreement with Entelos, that,
among other things, granted Entelos a non-exclusive, fully paid-up, royalty-free
world-wide license to make, have made, use, import, offer to sell and sell
products and practice any systems, methods or other inventions covered by the
patents. Pursuant to a stipulation and order of dismissal issued by the United
States District Court for the Northern District of California, all claims and
counterclaims in the above-described action were dismissed with prejudice. The
Company did not pay any money to Entelos as part of the agreement, and
management does not believe that the settlement will have a material adverse
effect on future business activities of the Company.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
No matters were submitted during the fourth quarter of the year ended
December 31, 1999.
PART II
ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS
MARKET INFORMATION
The Company's Common Stock began trading on The NASDAQ SmallCap Market on
November 26, 1997 under the symbol "MSSI" and on the Boston Stock Exchange under
the symbol "MSI." In August 1999, the Company's Common Stock symbol changed to
"ILGN" on the NASDAQ SmallCap Market and "ILG" on the Boston Stock Exchange.
Prior to November 1997, there was no established trading market for the Common
Stock. The following table sets forth, for the periods indicated, the high and
low bid prices for the Common Stock, as reported by the NASDAQ SmallCap Market,
since the Common Stock commenced public
-17-
trading. The quotations represent prices in the over-the-counter market between
dealers and securities, and do not include retail markup, markdown or
commissions and may not necessarily represent actual transactions.
1999: HIGH LOW
---- ---
First Quarter.......................... $1.313 $0.406
Second Quarter ........................ $3.500 $0.781
Third Quarter.......................... $3.313 $1.500
Fourth Quarter......................... $9.000 $1.875
1998: HIGH LOW
---- ---
First Quarter.......................... $6.063 $2.938
Second Quarter ........................ $5.00 $3.50
Third Quarter.......................... $4.25 $1.313
Fourth Quarter......................... $2.125 $0.469
1997: HIGH LOW
---- ---
November 26 - December 31, 1997 ....... $9.00 $3.875
NUMBER OF SHAREHOLDERS
As of March 1, 2000, there were approximately 162 record holders of the
Company's Common Stock.
DIVIDENDS
The Company has not declared any dividends to date and does not plan to
declare any dividends in the foreseeable future.
SALE OF UNREGISTERED SECURITIES
Previously reported.
ITEM 6. SELECTED FINANCIAL DATA.
The following table sets forth financial data with respect to the Company
as of and for each of the five years ended December 31, 1999. The selected
financial data as of and for each of the five years ended December 31, 1999 have
been derived from the financial statements of the Company. The financial
statements and the reports thereon as of December 31, 1999, and 1998 and for the
years ended December 31, 1999, 1998 and 1997 are included elsewhere in this
Annual Report on Form 10-K. The information below should be read in conjunction
with the financial statements (and notes thereon) and Management's Discussion
and Analysis of Financial Condition and Results of Operations included in Item
7.
-18-
YEARS ENDED DECEMBER 31,
--------------------------------------------------------------------------------
1999 1998 1997 1996 1995
------------ ------------ ------------ ------------ ------------
Revenues ...................................... $ 477,497 $ 412,942 $ 195,928 $ 1,918,879 $ 1,872,932
Gross Profit .................................. 276,315 196,658 29,486 1,371,113 1,505,412
Expenses:
Research and Development ................... 3,570,845 2,799,220 1,223,468 958,249 582,595
Selling, general and administrative ........ 2,904,210 7,220,444 2,868,057 1,162,768 755,785
Operating income (loss) ....................... (6,198,740) (9,803,006) (4,062,039) (749,904) 167,032
Other income (expense):
Interest Income ............................ 107,446 379,054 53,889 8,561 35
Interest expense ........................... (59,189) (94,597) (485,062) (34,229) (14,300)
Other income (expense) ..................... 11,880 11,124 -- (6,934) --
Net income (loss) ............................. (6,138,603) (9,508,275) (4,494,062) (788,546) 150,012
Net income (loss)applicable to common
stock ....................................... (11,138,603) (9,508,275) (4,494,062) (788,546) 150,012
Basic and diluted loss per common share ....... (1.15) (1.72) (1.19) (.18) .03
Weighted-average common shares
outstanding ................................. 9,720,621 5,540,895 3,773,474 4,288,436 4,288,436
AS OF DECEMBER 31,
--------------------------------------------------------------------------------
1999 1998 1997 1996 1995
------------ ------------ ------------ ------------ ------------
Balance Sheet Data:
Cash, cash equivalents and marketable
securities .................................. $ 2,656,116 $ 2,432,271 $ 12,012,772 55,966 73,000
Working Capital (deficit) ..................... 1,967,943 1,462,748 11,186,863 (735,986) 242,000
Total Assets .................................. 3,176,159 3,672,890 12,823,376 311,962 458,000
Long-term debt and capital lease
obligations, less current portion ........... 99,246 604,507 580,739 200,834 --
Shareholders equity ........................... $ 2,153,178 $ 1,846,348 11,286,889 (699,748) 299,000
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
GENERAL OVERVIEW
Interleukin Genetics, Inc., a Texas corporation ("ILGN" or the "Company")
develops and commercializes genetic diagnostic tests and medical research tools.
The Company's efforts are focused on genetic factors that affect the rate of
progression of clinical disease through their influence on common host systems.
The Company's first genetic test, PST(R), a test predictive of risk for
periodontal disease, is currently marketed in the United States, Europe and
Israel. Products under development include tests predictive of risk for
osteoporosis, coronary artery disease, diabetic retinopathy, asthma, pulmonary
fibrosis and meningitis/sepsis. The Company believes by combining genetic risk
assessment with specific therapeutic strategies, improved clinical outcomes and
more cost-effective management of these common diseases are achieved. ILGN also
develops and licenses its medical research tools, including BioFusion(R), to
pharmaceutical companies. BioFusion, a proprietary enabling system for
diagnostic and drug discovery and development, is a computer modeling system
that integrates genetic and other sub-cellular behavior, system functions, and
clinical symptoms to simulate complex diseases. This system allows for the
utilization of the
-19-
rapidly increasing databases of gene expression, cell biology, prognostic,
pharmacogenomic and predictive medicine databases being generated in companies
and academic centers worldwide.
The Company has followed a strategy of working with strategic partners at
the fundamental discovery stage. This strategy has given the Company access to
discoveries while reducing up-front research expenses. Since 1994, the Company
has had a strategic alliance with the Department of Molecular and Genetic
Medicine at Sheffield University in the United Kingdom ("Sheffield"). Under this
alliance, Sheffield has provided to the Company the fundamental discovery and
genetic analysis from Sheffield's research laboratories and the Company has
focused on product development, including clinical trials, and the
commercialization of these discoveries. In October 1999, the Company entered
into a new arrangement (the "Agreement") with Sheffield replacing the research
and development agreement that had been in place with Sheffield since 1996.
Under the Agreement, the Company will undertake the development and
commercialization of certain discoveries resulting from Sheffield's research.
The Agreement with Sheffield is a five-year agreement with an automatic yearly
renewal. Pursuant to this new arrangement, the Company issued an aggregate of
475,000 shares of its Common Stock to Sheffield and its investigators in
exchange for the transfer of certain patent rights and the relinquishment of
proceeds interests held by Sheffield and its investigators under all project
agreements. The Company also entered into a research and development services
agreement with Sheffield which automatically renews in one-year increments. In
connection with this new arrangement, the Company entered into a five- year
consulting agreement with Sheffield's key collaborator. The Company anticipates
entering into additional collaborative arrangements with Sheffield and other
parties in the future.
In December 1997, the Company entered into an agreement with Medicadent, a
French corporation ("Medicadent"), to market and sell PST in France. In August
1998, the Company entered into an agreement with H.A. Systems, Ltd. to market
and sell PST in Israel. Medicadent commenced offering PST in France in June
1998, and the Company H.A. Systems commenced offering PST in Israel in early
1999. In March 1999, the Company entered into an agreement with the Straumann
Company to market and sell PST in the United States and Puerto Rico. Straumann
launched its PST promotional activities in April 1999. In April 1999, the
Company entered into an agreement with Dumex, a subsidiary of AlPharma, a
pharmaceutical manufacturer, to market and sell PST in nine European countries
(Austria, Denmark, Finland, Germany, Ireland, Norway, Sweden, Switzerland and
the U.K.). Dumex is well known in Europe as a manufacturer of oral health care
products used by periodontists. No assurances can be made regarding the
commercial acceptance of PST. The Company anticipates additional international
agreements for the distribution of PST in 2000, but no assurances can be made
that such agreements will be entered into by the Company.
The Company has been awarded four U.S. patents, and has sixteen U.S.
patent applications pending. The U.S. Patent & Trademark Office awarded patents
to the Company for its osteoporosis and periodontal disease susceptibility tests
and two patent awards for its biologic modeling technology called BioFusion(R),
which is used by the Company in the discovery, development and commercialization
process.
RESULTS OF OPERATIONS
COMPARISON OF YEAR ENDED DECEMBER 31, 1999 TO YEAR ENDED DECEMBER 31, 1998
Revenue for the year ended December 31, 1999 was $477,497 as compared to
$412,942 for the year ended December 31, 1998, representing an increase of
$64,555 or 16%. The increase in revenue is primarily attributable to higher
average selling price per PST test. Cost of revenues was $201,182 for the year
ended December 31, 1999 as compared to $216,284 for the same year period in
1998, representing a decrease of $15,102 or 7%. This decrease is primarily
attributable to lower laboratory costs for processing PST tests.
For the year ended December 31, 1999, the Company had research and
development expenses of $3,570,845 as compared to $2,799,220 for 1998, an
increase of $771,625 or 28%. This increase was primarily
-20-
due to $1,128,125 of non-cash expense associated with issuance of 475,000 shares
of common stock to the University of Sheffield and its investigators in
conjunction with the new arrangement with Sheffield and its investigators
entered into in October 1999.
Selling, general and administrative expenses decreased for 1999 to
$2,904,210 from $7,200,444 in 1998, a decrease of $4,296,234 or 60%. The
decrease reflects the reduction in personnel costs as the Company shifted from
an internal sales staff to the use of outside distributors to sell its PST
tests.
Interest income decreased to $107,446 in 1999 from $379,054 in 1998. This
decrease is attributable to the reduction in the unused net proceeds of the
initial public offering and subsequent private placements as the proceeds are
used for ongoing Company operations and a $585,992 reduction in the Company's
debt obligations. The reduction in the Company's debt obligations is also the
primary reason for the interest expense decreasing from $94,597 in 1998 to
$59,189 in 1999, a decrease of $35,408 or 37%.
Net losses decreased to $6,138,603 in for the year ended December 31,
1999, as compared to $9,508,275 in 1998, a decrease of $3,369,672 or 35%. Such
decreased loss is a result of the decreased expenses set forth above.
COMPARISON OF YEAR ENDED DECEMBER 31, 1998 TO YEAR ENDED DECEMBER 31,
1997.
Revenue for the year ended December 31, 1998 was $412,942 as compared to
$195,928 for the year ended December 31, 1997, representing an increase of
$217,014 or 111%. The increase in revenue is primarily attributable to sales of
PST, the Company's first genetic test which was made commercially available in
the fourth quarter of 1997. Cost of revenues was $216,284 for the year ended
December 31, 1998 as compared to $166,442 for the same period in 1997,
representing an increase of 30%. This increase is a result of the increase in
sales, offset by the Company's ability to take advantage of volume processing
discounts provided to it by its outside laboratory vendors.
For the year ended December 31, 1998, the Company had research and
development expenses of $2,799,220 as compared to $1,223,468 for 1997, an
increase of $1,575,752 or 129%. This increase was due to our continued
investment in genetic research projects. In addition to the full time employment
of key scientists for our coronary artery disease and osteoporosis genetic
susceptibility tests, and for new clinical trials which have commenced and are
continuing to run for the same two tests, the Company continues to perform
science enhancement studies for our PST product, as well as invest in our
previously disclosed research projects related to diabetic retinopathy and
asthma.
One additional factor in the increase of research and development
expenses, as discussed above, is the write-down of capitalized patent expenses.
The resulting charge, taken in the fourth quarter of 1998, was $886,534, or 32%,
of research and development expenses for the year. Management believes it is
appropriate to expense these costs after consideration of their current
development strategy and available capital.
Selling, general and administrative expenses increased for 1998 to
$7,200,444 from $2,868,057 for 1997, an increase of $4,332,387 or 151%. This
increase is primarily attributable to building the infrastructure required to
support commercial operations and the increased marketing and sales efforts
required to support the Company's genetic susceptibility testing business.
Additionally, general and administrative expenses increased to support the
research and development efforts of the Company, and due to increased legal and
accounting expenses related to complying with SEC reporting obligations.
During the second quarter of 1998, the Company consolidated its corporate
headquarters from Newport Beach, California into the Company's San Antonio
Research Facility. As a result of this relocation, the Company amended its
existing lease in San Antonio to extend the term and expand its premises. The
-21-
amended lease expires on May 31, 2003 and extends its square footage from
approximately 1,961 square feet to 8,131 square feet. Also, as a result of the
move from California, the Company has subleased its leased office space in
Newport Beach. The sublease expires on the same date of the Company's lease,
April 30, 2001.
Interest income for the year ended December 31, 1998 increased to $379,054
from $53,889 for 1997. Such increase is attributable entirely to the interest
income generated by the unused net proceeds of the initial public offering.
Interest expense of $94,597 was incurred during the year ended December 31,
1998, a decrease of 81% from $485,062 over the same period in 1997. Such
decrease is attributable to a decrease in the amount of the Company's debt
obligations, which were substantially reduced with the net proceeds of the
Company's initial public offering.
Net losses increased to $9,508,275 for the year ended December 31, 1998,
as compared to $4,494,062 for the same period in 1997, an increase of $5,014,213
or 112%. Such increased loss is a result of the increased expenses set forth
above.
LIQUIDITY AND CAPITAL RESOURCES
The Company believes that its cash and cash equivalents are the most
significant indicators of the Company's liquidity position. As of December 31,
1999, the Company had cash and cash equivalents of $2,656,116. The cash and cash
equivalents position generated interest income of $28,166 in the fourth quarter
of 1999, and $107,446 for the year.
Net cash used in operating activities was $4,420,167 during the year ended
December 31, 1999 as compared to $8,454,858 used during 1998. Marketable
securities increased from zero in 1998 to $1,987,500 at December 31, 1999 as the
Company purchased U.S. Treasury notes with the unused proceeds from the private
placement of $5,000,000 of convertible preferred stock in June 1999. Accounts
payable decreased from $278,773 in 1998 to $134,968 in 1999. This decrease was
primarily due to the decreased level of operating expenses in late 1999.
Additionally, the Company entered into an agreement with a distributor whereby
the distributor paid in advance for licensing fees, resulting in Prepaid
distributor fees increasing from zero in 1998 to $65,000 in 1999. The current
portion of long-term debt decreased from $81,432 in 1998 to zero in 1999 due to
the Company's retirement of all outstanding debt in 1999.
The Company's investing activities used cash of $1,752,116 in the year ended
December 31, 1999 and provided cash of $5,036,678 in 1998. During the year ended
December 31, 1999, the Company shifted excess cash from Cash and cash
equivalents into Marketable securities to earn a preferred interest rate.
Additionally, during 1998, the Company received proceeds from the maturity of
investments of $6,226,795 as a result of the maturity of U.S. Treasury bills
previously invested in, partially offset by reinvestment in a certificate of
deposit. Investing activities were comprised primarily from the maturing of
investments and a certificate of deposit and the purchase of investments.
Financing activities provided $4,408,628 in 1999 and used $154,608 in 1998.
During 1999, the Company received $4,706,927 in net proceeds for the issuance of
convertible preferred stock and $380,545 in proceeds for the issuance of common
stock, as compared to $5,734 for common stock issued in 1998. In 1999, the
Company received proceeds from long term borrowings of $10,688 as compared to
$617,813 in 1998.
In January of 2000, the Company received $ 4,733,084 in net proceeds from a
private placement of 832,667 shares of common stock.
The Company currently does not have any commitments for material capital
expenditures. The Company's obligation at December 31, 1999 for capitalized
lease obligations totaled $163,123, of which $99,246 is classified as long-term
and $63,877 is classified as current.
-22-
The Company anticipates that its existing cash and cash equivalents,
together with anticipated interest income and revenue, will be sufficient to
conduct its operations as planned until September 2001. However, the Company's
future capital requirements are anticipated to be substantial, and the Company
does not have commitments for additional capital at this time. Such capital
requirements are expected to arise from the commercial launch of additional
genetic tests, continued marketing and sales efforts for PST, continued research
and development efforts, the protection of the Company's intellectual property
rights (including preparing and filing of patent applications), as well as
operational, administrative, legal and accounting expenses. The Company plans to
raise capital through equity and/or debt issuance when, and if, such capital is
available to it. THERE CAN BE NO ASSURANCE THAT THE COMPANY WILL BE ABLE TO
RAISE ANY ADDITIONAL NECESSARY CAPITAL. IF ADDITIONAL AMOUNTS CANNOT BE RAISED,
THE COMPANY WOULD SUFFER MATERIAL ADVERSE CONSEQUENCES TO ITS BUSINESS,
FINANCIAL CONDITION AND RESULTS OF OPERATIONS AND WOULD LIKELY BE REQUIRED TO
SEEK PROTECTION UNDER THE UNITED STATES BANKRUPTCY LAWS.
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK.
The Company maintains an investment portfolio consisting of securities of
U.S Treasury Notes. The securities held in the Company's investment portfolio
are subject to interest rate risk. Changes in interest rates affect the fair
market value of these securities. After a review of the Company's marketable
securities as of December 31, 1999, the Company has determined that in the event
of a hypothetical ten percent increase in interest rates, the resulting decrease
in fair market value of the Company's marketable investment securities would be
insignificant to the financial statements as a whole.
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
The Consolidated Financial Statements of the Company, together with the
Independent Auditors Report thereon of each of Arthur Andersen LLP and Singer
Lewak Greenbaum & Goldstein LLP, appears on pages F-2 through F-23 of this
report. See the "Index to Financial Statements" on page F-1 of this report.
ITEM 9. CHANGES AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE
Previously reported.
-23-
PART III
ITEM 10. DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS;
COMPLIANCE WITH SECTION 16(A) OF THE EXCHANGE ACT.
Information required under this Item will be contained in the Company's
Proxy Statement for its 2000 Annual Meeting, which is incorporated herein by
reference.
ITEM 11. EXECUTIVE COMPENSATION
Information required under this Item will be contained in the Company's
Proxy Statement for its 2000 Annual Meeting, which is incorporated herein by
reference.
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
Information required under this Item will be contained in the Company's
Proxy Statement for its 2000 Annual Meeting, which is incorporated herein by
reference.
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
Information required under this Item will be contained in the Company's
Proxy Statement for its 2000 Annual Meeting, which is incorporated herein by
reference.
PART IV
ITEM 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES, AND REPORTS ON FORM 8-K.
(A) DOCUMENTS FILED AS PART OF REPORT
1. Financial Statements:
The Consolidated Financial Statements of the Company and the related
report of the Company's independent public accountants thereon have been
filed under Item 8 hereof.
2. Financial Statement Schedules:
The information required by this item is not applicable.
3. Exhibits:
The exhibits listed below are filed as part of or incorporated by
reference in this report. Where such filing is incorporated by reference
to a previously filed document, such document is identified in
parentheses. See the Index of Exhibits included with the Exhibits filed as
a part of this report.
EXHIBIT NO. IDENTIFICATION OF EXHIBIT
3.1 Articles of Incorporation of the Company, as amended (incorporated
herein by reference to the Company's Quarterly Report on Form 10-QSB
filed November 15, 1999).
-24-
3.2 Amended and Restated Bylaws of the Company, as amended (incorporated
herein by reference to Exhibits 3.3 and 3.4 of the Company's
Registration Statement No. 333-37441 on Form SB-2 filed October 8,
1997).
4.1 Form of Stock Certificate representing Common Stock, no par value,
of the Company (incorporated herein by reference to Exhibit 4.1 of
the Company's Registration Statement No. 333-37441 on Amendment No.
1 to Form SB-2 filed October 29, 1997).
4.2 Form of Representative's Warrant (incorporated herein by reference
to Exhibit 4.2 of the Company's Registration Statement No. 333-37441
on Form SB-2 filed October 8, 1997).
4.3 Form of Security Agreement (incorporated herein by reference to
Exhibit 4.4 of the Company's Registration Statement No. 333-37441 on
Form SB-2 filed October 8, 1997).
4.4 Form of Warrant Agreement (incorporated herein by reference to
Exhibit 4.5 of the Company's Registration Statement No. 333-37441 on
Form SB-2 filed October 8, 1997).
4.5 Form of Warrant Certificate (incorporated herein by reference to
Exhibit 4.6 of the Company's Registration Statement No. 333-37441 on
Form SB-2 filed October 8, 1997).
4.6 Warrant dated June 15, 1999, granted to Fine Equities, Inc.
(incorporated herein by reference to Exhibit 4.2 of the company's
Quarterly Report on Form 10-QSB field August 16, 1999).
10.1 Loan Agreement dated June 27, 1997, between the Company and Bank of
America (incorporated herein by reference to Exhibit 4.7 of the
Company's Registration Statement No. 333-37441 on Form SB-2 filed
October 8, 1997).
10.2+ Research Support Agreement and Amendments to Various Existing
Project Agreements dated April 1, 1998, between the Company and The
University of Sheffield (incorporated herein by reference to Exhibit
10.2 of the Company's Registration Statement No. 333-37441 on Form
SB-2 filed October 8, 1997).
10.3+ Laboratory Services Agreement dated December 7, 1996, between the
Company and Baylor College of Medicine (incorporated herein by
reference to Exhibit 10.13 of the Company's Registration Statement
No. 333-37441 on Form SB-2 filed October 8, 1997).
10.4 Lease Agreement dated March 21, 1996, between the Company and Koll
Center Newport Number 9 (incorporated herein by reference to Exhibit
10.14 of the Company's Registration Statement No. 333-37441 on Form
SB-2 filed October 8, 1997).
10.5 Lease Agreement dated October 23, 1997, between the Company and
Diamond Shamrock Leasing, Inc. (incorporated herein by reference to
Exhibit 10.16 of the Company's Registration Statement No. 333-37441
on Form SB-2 filed October 8, 1997).
10.6 Interleukin Genetics, Inc. 1996 Equity Incentive Plan (incorporated
herein by reference to Exhibit 10.17 of the Company's Registration
Statement No. 333-37441 on Form SB-2 filed October 8, 1997).
10.7 Amendment to the Interleukin Genetics, Inc. 1996 Equity Incentive
Plan (incorporated herein by reference to Exhibit 10.18 of the
Company's Registration Statement No. 333- 37441 on Form SB-2 filed
October 8, 1997).
-25-
10.8 Form of Stock Option Agreement (incorporated herein by reference to
Exhibit 10.19 of the Company's Registration Statement No. 333-37441
on Form SB-2 filed October 8, 1997).
10.9 Stock Option Exercise Agreement (incorporated herein by reference to
Exhibit 10.20 of the Company's Registration Statement No. 333-37441
on Form SB-2 filed October 8, 1997).
10.10+ Exclusive Independent Representative Agreement dated December 1,
1997, between the Company and Medicadent, a French corporation
(incorporated herein by reference to Exhibit 10.21 of the Company's
Annual Report on Form 10-KSB filed March 31, 1998).
10.11 Consulting and Severance Agreement dated October 28, 1998, between
the Company and Michael G. Newman (incorporated herein by reference
to Exhibit 10.22 of the Company's Annual Report on Form 10-KSB filed
March 31, 1999).
10.12 Amendment to Employment Agreement dated to be effective as of
November 17, 1998, between the Company an Paul J. White
(incorporated herein by reference to Exhibit 10.23 of the Company's
Annual Report on Form 10-KSB filed March 31, 1999).
10.13 Amendment to Employment Agreement dated to be effective as of
November 17, 1998, between the Company an Kenneth S. Kornman
(incorporated herein by reference to Exhibit 10.24 of the Company's
Annual Report on Form 10-KSB filed March 31, 1999).
10.14 Letter Agreement dated January 6, 1997, between the Company and U.
Spencer Allen, as amended effective December 1, 1998 (incorporated
herein by reference to Exhibit 10.25 of the Company's Annual Report
on Form 10-KSB filed March 31, 1999).
10.15 Business Loan Agreement between the Company and Bank of America
dated June 5, 1998 (incorporated herein by reference to Exhibit 10.1
of the Company's Quarterly Report on Form 10-QSB filed May 17,
1999).
10.16+ Distribution Agreement between the Company and The Straumann Company
dated March 25, 1999 (incorporated herein by reference to Exhibit
10.2 of the company's Quarterly Report on Form 10-QSB filed May 17,
1999).
10.17 Consulting Services Agreement dated June 1, 1999, between the
Company and Philip R. Reilly (incorporated herein by reference to
Exhibit 10.1 of the Company's Quarterly Report on Form 10-QSB filed
August 16, 1999).
10.18 Non-Qualified Stock Option Agreement dated June 1, 1999, between the
Company and Philip R. Reilly (incorporated herein by reference to
Exhibit 10.2 of the Company's Quarterly Report on Form 10-QSB filed
August 16, 1999).
10.19 Form of Subscription Agreement (incorporated herein by reference to
Exhibit 10.3 of the Company's Quarterly Report on Form 10-QSB filed
August 16, 1999).
10.20 Agency Agreement dated June 15, 1999, between the Company and Fine
Equities, Inc. (incorporated herein by reference to Exhibit 10.4 of
the Company's Quarterly Report on Form 10-QSB filed August 16,
1999).
-26-
10.21+ Research and Technology Transfer Agreement dated effective July 1,
1999, between the Company and the University of Sheffield
(incorporated herein by reference to Exhibit 10.1 of the Company's
Quarterly Report on Form 10-QSB filed November 15, 1999).
10.22+ Research Support Agreement dated effective July 1, 1999, between the
Company and the University of Sheffield (incorporated herein by
reference to Exhibit 10.2 of the Company's Quarterly Report on Form
10-QSB filed November 15, 1999).
10.23+ Consulting Agreement dated effective July 1, 1999, between the
Company and Gordon Duff, PhD, FRCP (incorporated herein by reference
to Exhibit 10.3 of the Company's Quarterly Report on Form 10-QSB
filed November 15, 1999).
10.24 Non-Qualified Stock Option Agreement dated November 30, 1999 between
the Company and Philip R. Reilly (incorporated herein by reference
to Exhibit 4.5 to the Company's Registration Statement No. 333-32538
on Form S-8 filed March 15, 2000).
10.25* Employment Agreement dated December 1, 1999 between the Company and
Kenneth S. Kornman.
10.26* Employment Agreement dated April 1, 2000 between the Company and
Philip R. Reilly.
10.27* Severance Agreement dated September 20, 1999 between the Company and
Paul White.
16.1 Letter from Singer Lewak Greenbaum & Goldstein LLP dated October 26,
1998, to the Securities and Exchange Commission pursuant to Item
304(a)(3) of Regulation S-K (incorporated herein by reference to
Exhibit 16 of the Company's current report on Form 8-K filed
November 2, 1998).
21.1 Subsidiaries of the Company
NAMES UNDER WHICH
NAME INCORPORATED SUBSIDIARY DOES BUSINESS
- ----------------------------------------------------- ---------------------------- ------------------------
Medical Science Systems France E.U. France N/A
Interleukin Genetics Laboratory Services, Inc. Delaware N/A
Interleukin Genetics, Inc. Delaware N/A
23.1* Consent of Arthur Andersen LLP
23.2* Consent of Singer Lewak Greenbaum & Goldstein LLP
27.* Financial Data Schedule.
- -----------------
* Filed herewith.
+ Confidential treatment has been requested with respect to certain portions
of this exhibit. Omitted portions have been filed separately with the
Securities and Exchange Commission.
(b) REPORTS ON FORM 8-K
-27-
The Company filed a report on Form 8-K October 8, 1999 to report a new
contractual arrangement with the University of Sheffield.
The Company filed a report on Form 8-K December 17, 1999 to report the
deadline for shareholder proposals for the annual meeting.
-28-
In accordance with Section 13 or 15(d) of the Exchange Act, the registrant
caused this amended report to be signed on its behalf by the undersigned,
thereunto duly authorized.
INTERLEUKIN GENETICS, INC.
Date: April 12, 2000 By: U. SPENCER ALLEN
U. Spencer Allen
Chief Financial Officer, Secretary and Treasurer
In accordance with the Exchange Act, this report has been signed below by
the following persons on behalf of the registrant and in the capacities and on
the date indicated.
SIGNATURES TITLE DATE SIGNED
---------- ----- -----------
/s/ PHILIP R. REILLY Chairman of the Board of Directors April 12, 2000
Philip R. Reilly and Chief Executive Officer
/s/ KENNETH S. KORNMAN President and Director April 12, 2000
Kenneth S. Kornman
/s/ U. SPENCER ALLEN Chief Financial Officer, Secretary and Treasurer April 12, 2000
U. Spencer Allen (PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER)
/s/ THOMAS A. MOORE Director April 12, 2000
Thomas A. Moore
/s/ EDWARD M. BLAIR, JR. Director April 12, 2000
Edward M. Blair, Jr.
/s/ GARY L. CROCKER Director April 12, 2000
Gary L. Crocker
-29-
INTERLEUKIN GENETICS, INC.
CONSOLIDATED FINANCIAL STATEMENTS
AS OF DECEMBER 31, 1999, 1998 AND 1997
TOGETHER WITH AUDITORS' REPORT
INTERLEUKIN GENETICS, INC.
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
Page
REPORT OF INDEPENDENT PUBLIC ACCOUNTANTS F-2
REPORT OF INDEPENDENT PUBLIC ACCOUNTANTS F-3
CONSOLIDATED FINANCIAL STATEMENTS:
Consolidated Balance Sheets - December 31, 1999 and 1998 F-4
Consolidated Statements of Operations - For the Years Ended
December 31, 1999, 1998 and 1997 F-6
Consolidated Statements of Shareholders' Equity - For the Years Ended
December 31, 1999, 1998 and 1997 F-7
Consolidated Statements of Cash Flows - For the Years Ended
December 31, 1999, 1998 and 1997 F-8
Notes to Consolidated Financial Statements F-10
F-1
REPORT OF INDEPENDENT PUBLIC ACCOUNTANTS
To Interleukin Genetics, Inc.:
We have audited the accompanying consolidated balance sheets of Interleukin
Genetics, Inc. (a Texas corporation), as of December 31, 1999 and 1998, and the
related consolidated statements of operations, shareholders' equity and
comprehensive income and cash flows for the years then ended. These financial
statements are the responsibility of the Company's management. Our
responsibility is to express an opinion on these financial statements based on
our audit.
We conducted our audits in accordance with auditing standards generally accepted
in the United States. Those standards require that we plan and perform the audit
to obtain reasonable assurance about whether the financial statements are free
of material misstatement. An audit includes examining, on a test basis, evidence
supporting the amounts and disclosures in the financial statements. An audit
also includes assessing the accounting principles used and significant estimates
made by management, as well as evaluating the overall financial statement
presentation. We believe that our audits provide a reasonable basis for our
opinion.
In our opinion, the financial statements referred to above present fairly, in
all material respects, the financial position of Interleukin Genetics, Inc., as
of December 31, 1999 and 1998, and the results of its operations and its cash
flows for the years then ended in conformity with accounting principles
generally accepted in the United States.
/s/ ARTHUR ANDERSEN LLP
San Antonio, Texas
March 29, 2000
F-2
REPORT OF INDEPENDENT PUBLIC ACCOUNTANTS
To the Board of Directors and Shareholders
Medical Science Systems, Inc.
We have audited the consolidated statements of operations, shareholders' equity,
and cash flows of Medical Science Systems, Inc. and subsidiary as of December
31, 1997. These financial statements are the responsibility of the Company's
management. Our responsibility is to express an opinion on these financial
statements based on our audit.
We conducted our audit in accordance with generally accepted auditing standards.
Those standards require that we plan and perform the audit to obtain reasonable
assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audit provides a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly, in
all material respects, the consolidated results of Medical Science Systems, Inc.
and subsidiary's operations and their consolidated cash flows for the year ended
December 31, 1997 in conformity with generally accepted accounting principles.
SINGER LEWAK GREENBAUM & GOLDSTEIN LLP
Los Angeles, California
March 13, 1998
F-3
INTERLEUKIN GENETICS, INC.
CONSOLIDATED BALANCE SHEETS
DECEMBER 31, 1999 AND 1998
- --------------------------------------------------------------------------------
ASSETS
1999 1998
---------- ----------
CURRENT ASSETS:
Cash and cash equivalents ..................... $ 668,616 $2,432,271
Marketable securities ......................... 1,987,500 --
Accounts receivable, net of allowance for
doubtful accounts of $55,300 in 1999 and
$20,959 in 1998 ............................. 103,002 125,086
Prepaid expenses .............................. 132,560 127,426
---------- ----------
Total current assets ............. 2,891,678 2,684,783
FURNITURE AND EQUIPMENT, net ..................... 284,481 458,107
OTHER ASSETS ..................................... -- 530,000
---------- ----------
TOTAL ASSETS ..................... $3,176,159 $3,672,890
========== ==========
The accompanying notes are an integral part of
these consolidated financial statements.
F-4
INTERLEUKIN GENETICS, INC.
CONSOLIDATED BALANCE SHEETS (CONTINUED)
DECEMBER 31, 1999 AND 1998
- --------------------------------------------------------------------------------
LIABILITIES AND SHAREHOLDERS' EQUITY
1999 1998
------------ ------------
CURRENT LIABILITIES:
Accounts payable ............................. $ 134,968 $ 278,773
Accrued expenses ............................. 400,281 433,859
Notes payable ................................ 1,797 47,813
Deferred revenue ............................. 322,812 275,321
Current portion of long-term debt ............ -- 81,432
Current portion of capitalized lease
obligations ................................ 63,877 104,837
------------ ------------
Total current liabilities ................. 923,735 1,222,035
LONG-TERM DEBT, less current portion ............ -- 447,856
CAPITALIZED LEASE OBLIGATIONS, less current
portion ....................................... 99,246 156,651
------------ ------------
Total liabilities ......................... 1,022,981 1,826,542
------------ ------------
COMMITMENTS AND CONTINGENCIES (Note 9)
SHAREHOLDERS' EQUITY:
Preferred stock, no par value 5,000,000 shares
authorized none issued and outstanding .... -- --
Common stock, no par value 50,000,000 shares
authorized in 1999 and 10,000,000 shares
authorized in 1998, 17,223,302 and
5,548,470 shares issued and outstanding in
1999 and 1998, respectively ............... 23,177,865 16,719,933
Accumulated deficit .......................... (21,012,188) (14,873,585)
Other comprehensive loss ..................... (12,499) --
------------ ------------
Total shareholders' equity ................ 2,153,178 1,846,348
------------ ------------
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $ 3,176,159 $ 3,672,890
============ ============
The accompanying notes are an integral part of
these consolidated financial statements.
F-5
INTERLEUKIN GENETICS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE YEARS ENDED DECEMBER 31, 1999, 1998, AND 1997
- --------------------------------------------------------------------------------
1999 1998 1997
------------ ------------ ------------
REVENUE .................................. $ 477,497 $ 412,942 $ 195,928
COST OF REVENUE .......................... 201,182 216,284 166,442
------------ ------------ ------------
GROSS PROFIT ............................. 276,315 196,658 29,486
------------ ------------ ------------
EXPENSES:
Research and development .............. 3,570,845 2,799,220 1,223,468
Selling, general, and administrative .. 2,904,210 7,200,444 2,868,057
------------ ------------ ------------
Total expenses ..................... 6,475,055 9,999,664 4,091,525
------------ ------------ ------------
LOSS FROM OPERATIONS ..................... (6,198,740) (9,803,006) (4,062,039)
------------ ------------ ------------
OTHER INCOME (EXPENSE):
Interest income ....................... 107,446 379,054 53,889
Interest expense ...................... (59,189) (94,597) (485,062)
Other income .......................... 11,880 11,124 --
------------ ------------ ------------
Total other income (expense) ....... 60,137 295,581 (431,173)
------------ ------------ ------------
LOSS BEFORE PROVISION FOR INCOME TAXES ... (6,138,603) (9,507,425) (4,493,212)
PROVISION FOR INCOME TAXES ............... -- 850 850
------------ ------------ ------------
NET LOSS ................................. $ (6,138,603) $ (9,508,275) $ (4,494,062)
============ ============ ============
RECONCILIATION OF NET LOSS TO NET LOSS
APPLICABLE TO COMMON STOCK:
Net loss .............................. $ (6,138,603) $ (9,508,275) $ (4,494,062)
Amortization of the value of the
beneficial conversion feature of the
preferred stock ..................... 5,000,000 -- --
------------ ------------ ------------
NET LOSS APPLICABLE TO COMMON STOCK ...... $(11,138,603) $ (9,508,275) $ (4,494,062)
============ ============ ============
BASIC AND DILUTED LOSS PER COMMON SHARE .. $ (1.15) $ (1.72) $ (1.19)
============ ============ ============
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING 9,720,621 5,540,895 3,773,474
============ ============ ============
The accompanying notes are an integral part of
these consolidated financial statements.
F-6
INTERLEUKIN GENETICS, INC.
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY
AND COMPREHENSIVE INCOME
FOR THE YEARS ENDED DECEMBER 31, 1999, 1998, AND 1997
- --------------------------------------------------------------------------------
COMMON STOCK PREFERRED STOCK
----------------------------- -----------------------------
SHARES AMOUNT SHARES AMOUNT
------------ ------------ ------------ ------------
BALANCE, DECEMBER 31, 1996 .......... 3,295,539 $ 171,500 -- $ --
Net loss ............................ -- -- -- --
Common stock issued:
Private placements .............. 442,468 2,019,100 -- --
Initial public offering ......... 1,800,000 16,200,000 -- --
Offering costs ...................... -- (2,540,078) -- --
Stock options issued for reduction in
salary .......................... -- 445,132 -- --
Issuance of warrants resulting in
additional interest
expense ..................... -- 356,545 -- --
Exercise of stock options ........... 8,939 42,356 -- --
Repurchase of common stock .......... (6,051) (42,356) -- --
------------ ------------ ------------ ------------
BALANCE, DECEMBER 31, 1997 .......... 5,540,895 16,652,199 -- --
Net loss ............................ -- -- -- --
Common stock issued:
Employee stock
purchase plan ............... 7,575 5,734 -- --
Stock options issued:
For services rendered ........... -- 62,000 -- --
------------ ------------ ------------ ------------
BALANCE, DECEMBER 31, 1998 .......... 5,548,470 16,719,933 -- --
Net loss ............................ -- -- -- --
Unrealized loss on securities ....... -- -- -- --
Comprehensive Loss .................. -- -- -- --
Preferred stock issued:
Private placement ............... -- -- 2,200,000 4,706,927
Common stock issued:
Preferred stock conversion ...... 11,000,000 4,706,927 (2,200,000) (4,706,927)
For services rendered ........... 475,000 1,128,125 -- --
Exercise of stock options ....... 199,314 379,945 -- --
Employee stock
purchase plan ............... 518 600 -- --
Stock options issued:
For services rendered ........... -- 242,335 -- --
------------ ------------ ------------ ------------
BALANCE, DECEMBER 31, 1999 .......... 17,223,302 $ 23,177,865 -- $ --
============ ============ ============ ============
OTHER
ACCUMULATED COMPREHENSIVE
DEFICIT LOSS TOTAL
------------ ------------ ------------
BALANCE, DECEMBER 31, 1996 .......... $ (871,248) $ -- $ (699,748)
Net loss ............................ (4,494,062) -- (4,494,062)
Common stock issued:
Private placements .............. -- -- 2,019,100
Initial public offering ......... -- -- 16,200,000
Offering costs ...................... -- -- (2,540,078)
Stock options issued for reduction in
salary .......................... -- -- 445,132
Issuance of warrants resulting in
additional interest
expense ..................... -- -- 356,545
Exercise of stock options ........... -- -- 42,356
Repurchase of common stock .......... -- -- (42,356)
------------ ------------ ------------
BALANCE, DECEMBER 31, 1997 .......... (5,365,310) -- 11,286,889
Net loss ............................ (9,508,275) -- (9,508,275)
Common stock issued:
Employee stock
purchase plan ............... -- -- 5,734
Stock options issued:
For services rendered ........... -- -- 62,000
------------ ------------ ------------
BALANCE, DECEMBER 31, 1998 .......... (14,873,585) -- 1,846,348
Net loss ............................ (6,138,603) -- (6,138,603)
Unrealized loss on securities ....... -- (12,499) (12,499)
------------
Comprehensive Loss .................. -- -- (6,151,102)
Preferred stock issued:
Private placement ............... -- -- 4,706,927
Common stock issued:
Preferred stock conversion ...... -- -- --
For services rendered ........... -- -- 1,128,125
Exercise of stock options ....... -- -- 379,945
Employee stock
purchase plan ............... -- -- 600
Stock options issued:
For services rendered ........... -- -- 242,335
------------ ------------ ------------
BALANCE, DECEMBER 31, 1999 .......... $(21,012,188) $ (12,499) $ 2,153,178
============ ============ ============
The accompanying notes are an integral part of
these consolidated financial statements.
F-7
INTERLEUKIN GENETICS, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED DECEMBER 31, 1999, 1998, AND 1997
- --------------------------------------------------------------------------------
1999 1998 1997
----------- ----------- -----------
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss .......................................... $(6,138,603) $(9,508,275) $(4,494,062)
Adjustments to reconcile net loss to net
cash used in operating activities:
Depreciation and amortization .................. 194,611 178,283 74,368
Amortization (accretion) of investment
premium and discount ....................... 24,375 (219,082) (7,102)
Issuance of stock options for reduction
of salary .................................. -- -- 445,132
Issuance of stock options for services
rendered ................................... 242,335 62,000 --
Issuance of stock for services rendered ........ 1,128,125 -- --
Issuance of warrants resulting in
additional interest expense ................ -- -- 356,545
Write down of patents .......................... 241,932 886,534 --
Other noncash expenses ......................... -- 31,272 --
(Increase) decrease in:
Accounts receivable, net ................... 22,084 (87,971) (24,756)
Inventories ................................ -- 50,212 (50,212)
Prepaid expenses ........................... (5,134) (84,914) (42,512)
Due from shareholder ....................... -- -- 6,565
Increase (decrease) in:
Accounts payable ........................... (143,805) (271,414) 330,518
Accrued expenses ........................... (33,578) 306,177 70,595
Accrued officer compensation ............... -- -- (127,500)
Deferred revenue ........................... 47,491 202,320 73,001
----------- ----------- -----------
Net cash used in operating activities ............. (4,420,167) (8,454,858) (3,389,420)
----------- ----------- -----------
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of furniture and equipment .............. (15,810) (216,597) (60,504)
Increase in patents .............................. (241,932) (443,520) (307,710)
Purchase of investments .......................... (4,024,374) -- (6,000,611)
Proceeds from maturity of investments ............ 2,000,000 6,226,795 --
Proceeds from (investment in) certificate
of deposit ..................................... 530,000 (530,000) --
----------- ----------- -----------
Net cash provided by (used in) investing activities (1,752,116) 5,036,678 (6,368,825)
----------- ----------- -----------
The accompanying notes are an integral part of
these consolidated financial statements.
F-8
INTERLEUKIN GENETICS, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED)
FOR THE YEARS ENDED DECEMBER 31, 1999, 1998, AND 1997
- --------------------------------------------------------------------------------
1999 1998 1997
------------ ------------ ------------
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from sale of common stock ................ $ 380,545 $ 5,734 $ 18,219,100
Proceeds from sale of convertible preferred stock . 5,000,000 -- --
Payment of offering costs ......................... (293,073) -- (2,540,078)
Proceeds from note payable and long-term debt ..... 10,688 617,813 --
Principal payments on notes payable
and long-term debt ............................... (585,992) (673,012) (85,987)
Borrowings on line of credit, net ................. -- -- 146,277
Principal payments on capital lease obligations ... (103,540) (105,143) (31,974)
Proceeds from promissory notes .................... -- -- 1,780,000
Principal payments on promissory notes ............ -- -- (1,780,000)
------------ ------------ ------------
Net cash provided by (used in) financing activities 4,408,628 (154,608) 15,707,338
------------ ------------ ------------
Net increase (decrease) in cash and cash
equivalents ...................................... (1,763,655) (3,572,788) 5,949,093
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD ...... 2,432,271 6,005,059 55,966
------------ ------------ ------------
CASH AND CASH EQUIVALENTS, END OF PERIOD ............ $ 668,616 $ 2,432,271 $ 6,005,059
============ ============ ============
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Interest paid .................................... $ 59,189 $ 94,597 $ 126,149
============ ============ ============
Income taxes paid ................................ $ -- $ 1,660 $ 800
============ ============ ============
SUPPLEMENTAL SCHEDULE OF NONCASH INVESTING AND FINANCING ACTIVITIES:
During the years ended December 31, 1999, 1998 and 1997, the Company acquired
furniture and equipment of $5,175, $182,042 and $149,847, respectively, under
capitalized lease obligations.
During the year ended December 31, 1997, the Company converted its line of
credit for $500,000 into a note payable for $500,000. In addition, in a noncash
exchange, a shareholder exchanged 6,051 shares of the Company's common stock as
consideration for the exercise price of 8,939 stock options, which resulted in a
net issuance of 2,888 shares of common stock to this shareholder.
During the year ended December 31, 1999, the Company had other comprehensive
loss of $12,499, which represents an unrealized loss on marketable securities.
The accompanying notes are an integral part of
these consolidated financial statements.
F-9
INTERLEUKIN GENETICS, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 1999, 1998 AND 1997
NOTE 1 - COMPANY BACKGROUND AND UNCERTAINTIES
ORGANIZATION AND LINE OF BUSINESS
In August 1999, Medical Science Systems, Inc, was renamed Interleukin
Genetics, Inc. (the Company).
The Company is currently developing genetic diagnostic tests and medical
research tools. As of December 31, 1999, the Company has commercially
introduced one such product and is in various stages of development for
several others. Additionally, the Company provides research services under
contract to pharmaceutical companies. Such research services contributed
less than 10% of net revenue to the Company in 1999, 1998 and 1997.
The accompanying financial statements of the Company have been prepared on
the basis of accounting principles applicable to a going concern. Since
its inception, the Company has incurred cumulative net losses of
approximately $21.0 million, including losses of approximately $6.1
million during 1999, $9.5 million during 1998 and $4.5 million during
1997. For the years ended December 31, 1999, 1998 and 1997, the Company
reported negative cash flows from operating activities of approximately
$4.4 million, $8.5 million and $3.4 million, respectively. As a result of
these losses, available cash resources have been limited. While the
Company continues to pursue sources of capital, there can be no assurance
that they will be successful in these efforts.
During 1999, the Company raised approximately $5.1 million from a
preferred stock offering and shareholder stock option exercises.
Additionally, in January 2000, the Company completed a common stock
private placement which raised net proceeds of approximately $4.7 million.
(See Notes 7 and 12.) The Company believes that their current cash
resources are more than adequate to fund operations throughout the year
2000, however, absent additional equity or debt financings, they also
believe that those resources will be depleted in September 2001. To
address these future capital resources requirements, management of the
Company is currently in discussions with several potential strategic
partners regarding the up-front funding of certain of the Company's
research and development programs.
Commercial success of genetic susceptibility tests will depend upon their
acceptance as medically useful and cost-effective by patients, physicians,
dentists, other members of the medical and dental community, and
third-party payers. It is uncertain whether current genetic susceptibility
tests or others that the Company may develop will gain commercial
acceptance on a timely basis.
F-10
Research in the field of disease predisposing genes and genetic markers is
intense and highly competitive. The Company has many competitors in the
United States and abroad which have considerably greater financial,
technical, marketing, and other resources available. If the Company does
not discover disease predisposing genes or genetic markers and develop
susceptibility tests and launch such services or products before their
competitors, then revenues may be reduced or eliminated.
The Company's ability to successfully commercialize genetic susceptibility
tests depends on obtaining adequate reimbursement for such products and
related treatment from government and private health care insurers and
other third-party payers. Doctors' decisions to recommend genetic
susceptibility tests will be influenced by the scope and reimbursement for
such tests by third-party payers. If both third-party payers and
individuals are unwilling to pay for the test, then the number of tests
performed will significantly decrease, therefore resulting in a reduction
of revenues.
In July 1999, the Company entered into an agreement with Sheffield
University, whereby the Company will undertake the development and
commercialization of certain discoveries resulting from Sheffield
University's research. The agreement is non cancelable for discoveries on
which the parties have reached a specific agreement, but may be terminated
with or without cause by either party upon six-months notice with respect
to new discoveries on which the parties have not yet reached agreement. If
Sheffield University terminated the agreement, such termination could make
the discovery and commercial introduction of new products more difficult
or unlikely.
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
PRINCIPLES OF CONSOLIDATION
The consolidated financial statements include the accounts of the Company
and its wholly owned subsidiaries. All material intercompany accounts and
transactions have been eliminated.
ESTIMATES
The preparation of financial statements in conformity with generally
accepted accounting principles requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities and
disclosures of contingent assets and liabilities at the date of the
financial statements, as well as the reported amounts of revenues and
expenses during the reported periods. Actual results could differ from
those estimates.
FAIR VALUE OF FINANCIAL INSTRUMENTS
The Company measures its financial assets and liabilities in accordance
with generally accepted accounting principles. For certain of the
Company's financial instruments including cash and cash equivalents,
accounts receivable, accounts payable, and accrued expenses, the carrying
amounts approximate fair value due to their short maturities. The amounts
shown for long-term debt, notes payable and capital lease obligations also
approximate fair value because current interest rates and terms offered to
the Company for similar debt and lease agreements are substantially the
same.
F-11
CASH AND CASH EQUIVALENTS
For purposes of the statements of cash flows, the Company considers all
highly liquid investments purchased with original maturities of three
months or less to be cash equivalents. The Company maintains cash deposits
at primarily one bank. Deposits at this bank are insured by the Federal
Deposit Insurance Corporation up to $100,000. As of December 31, 1999,
uninsured portions of balances held at this financial institution totaled
$522,765. The Company has not experienced any losses in such accounts and
believes it is not exposed to any significant credit risk on cash and cash
equivalents.
MARKETABLE SECURITIES
Marketable securities are classified as available for sale and recorded at
current market value. Unrealized losses on such securities are reflected
as other comprehensive loss in shareholders' equity.
FURNITURE AND EQUIPMENT
Furniture and equipment, including equipment under capital leases, are
stated at cost, less accumulated depreciation and amortization.
Depreciation and amortization are provided using the straight-line method
over the estimated useful lives of three to five years. Leasehold
improvements are amortized over the life of the lease or the life of the
improvement, whichever is shorter. (See Note 4.)
Betterments, renewals, and extraordinary repairs that extend the life of
the asset are capitalized; other repairs and maintenance charges are
expensed as incurred. The cost and related accumulated depreciation
applicable to assets retired are removed from the accounts, and the gain
or loss on disposition is recognized in the statement of operations.
In 1999, the Company wrote-off $25,893 of leasehold improvements related
to a lease for office space. A portion of this office space was subleased
in 1999.
PATENTS
The Company expensed $241,932 in 1999 and $886,534 in 1998 of patent costs
incurred for existing products or those which may be developed in the
future. Management believes it is appropriate to expense these costs after
consideration of their current development strategy and available capital.
DISTRIBUTOR FEES
The Company has entered into multiple agreements for the distribution of
genetic susceptibility tests, both domestically and internationally.
Distributor fees are received based on the terms of each agreement and are
recognized ratably over the applicable agreement period. Distributor fees
received in advance totaled $65,000 at December 31, 1999, and are included
in deferred revenue in the accompanying consolidated balance sheets.
F-12
REVENUE RECOGNITION
Revenue from genetic susceptibility tests is recognized when the tests
have been completed and the results reported to the doctors. To the extent
test kits have been purchased but not yet submitted for test results, the
Company defers recognition of revenue. This amount is presented as
deferred revenue in the accompanying balance sheets. Contract revenues are
recognized ratably as services are provided based on a fixed contract
price or on negotiated hourly rates. Provision for anticipated losses on
fixed-price contracts is made in the period such losses are identified.
RESEARCH AND DEVELOPMENT
Research and development costs related to the development of new products
are expensed as incurred.
INCOME TAXES
The Company files a consolidated U.S. Federal income tax return which
includes all of its U.S. subsidiaries and a separate French federal income
tax return for the French subsidiary. Deferred income taxes are provided
when certain revenues and expenses are reported in periods which are
different for financial reporting purposes than for income tax reporting
purposes.
Deferred tax liabilities and assets are recorded based on the enacted
income tax rates which are expected to be in effect in the periods in
which the deferred tax liability or asset is expected to be settled or
realized. A change in the tax laws or rates results in adjustments to the
deferred tax liabilities and assets. The effect of such adjustments is
included in income in the period in which the tax laws or rates are
changed. Valuation allowances are established, when necessary, to reduce
deferred tax assets to the amount expected to be realized.
NET LOSS PER SHARE
The Company applies Statement of Financial Accounting Standards No. 128,
"Earnings per Share" ("SFAS 128"), in calculating basic and diluted loss
per share. Basic loss per share is determined by dividing net loss by the
weighted average number of shares of common stock outstanding during the
period. Diluted loss per share is determined by dividing net loss by the
weighted average number of shares of common stock and potential common
stock outstanding during the period. Stock options with an exercise price
below fair market value for any of the periods presented are considered
potential common stock.
Various stock options granted to vendors and employees in connection with
the Company's stock compensation plans were outstanding during the years
ended December 31, 1999 and 1998, but were not included in the computation
of diluted loss per share for such periods because the effect would have
been antidilutive. Options to purchase approximately 1.7 million shares of
common stock were outstanding at December 31, 1999.
F-13
NOTE 3 - ACCOUNTS RECEIVABLE
The changes in the allowance for doubtful accounts consisted of the
following:
DECEMBER 31
------------------------
1999 1998
-------- --------
Beginning of year .............................. $ 20,959 $ 1,000
Provision charged to expense ................... 48,000 20,000
Accounts written off, net of recoveries ........ (13,659) (41)
-------- --------
End of year .................................... $ 55,300 $ 20,959
======== ========
NOTE 4 - FURNITURE AND EQUIPMENT
Furniture and equipment useful lives and balances at December 31, 1999 and
1998, consisted of the following:
1999 1998
-------------- ------------
Computer equipment 3 years $ 299,004 $ 289,772
Lab equipment 5 years 6,578 -
Furniture and fixtures 5 years 32,304 32,304
Office equipment 3 years 37,769 37,769
Leasehold improvements 5 years 60,310 60,310
Equipment under capitalized
leases 3 to 5 years 377,627 372,452
-------------- ------------
813,592 792,607
Less- Accumulated depreciation
and amortization 529,111 334,500
-------------- ------------
TOTAL $ 284,481 $ 458,107
============== ============
NOTE 5 - NOTES PAYABLE AND LONG-TERM DEBT
In May 1998, outstanding notes payable were combined into a single-term
loan which matured in June 2005. The Company had provided a $530,000
certificate of deposit as security for this note. The principal balance of
$570,000 was due in monthly installments of $6,786, plus interest. In June
1999, the Company used the proceeds from the certificate of deposit to
repay the remaining principal balance.
NOTE 6 - INCOME TAXES
As of December 31, 1999, the Company had net operating loss (NOL) and
research tax credit carryforwards of approximately $18,750,000 and
$187,000, respectively, for federal income tax purposes, expiring in
varying amounts through the year 2019. The Company's ability to use its
NOL and credit carryforwards to reduce future taxes is subject to the
restrictions provided by Section 382 of the Internal Revenue Code of 1986
(the "Code").
F-14
These restrictions provide for limitations on the Company's utilization of
its NOL and credit carryforwards following a greater than 50% ownership
change during the prescribed testing period. As of December 31, 1999, the
Company had incurred such a change. As a result, approximately $15,619,000
of the Company's NOL carryforwards are limited in utilization to
approximately $825,000 annually. The annual limitation may result in the
expiration of the carryforwards prior to utilization.
As of December 31, 1999 and 1998, deferred tax assets (liabilities)
consisted of the following:
1999 1998
----------- -----------
Deferred tax assets:
Net operating loss carryforwards .......... $ 6,374,221 $ 4,432,995
Research tax credit carryforwards ......... 187,395 170,129
Accrual to cash adjustments ............... 211,650 242,924
Charitable contributions .................. -- 7,293
Stock options ............................. 90,092 --
Depreciation .............................. 22,496 --
Patents ................................... 60,856 83,265
----------- -----------
Total deferred tax assets ............. 6,946,710 4,936,606
Deferred tax liabilities:
Depreciation and amortization ............. -- (11,216)
----------- -----------
6,946,710 4,925,390
Valuation allowance for net deferred
tax assets ............................... 6,946,710 4,925,390
----------- -----------
NET DEFERRED TAX ASSETS ................... $ -- $ --
=========== ===========
As there is no assurance of future income, a 100% valuation reserve has
been established against the Company's deferred tax assets.
NOTE 7 - CAPITAL STOCK
PRIVATE PLACEMENT OF PREFERRED STOCK
Pursuant to a private placement which occurred in June 1999, the Company
issued 2,200,000 shares of its Series A Preferred Stock, no par value
(Series A Stock), for $5 million. In conjunction with this offering, the
placement agent received 200,000 shares of Series A Stock and a warrant to
purchase 1,000,000 shares of common stock at a price of $0.50 per share.
This warrant expires on June 16, 2004. Each share of the Series A Stock
was automatically converted into five shares of the Company's common stock
at a conversion price of $0.50 per share upon the approval of the private
placement by the Company's shareholders on August 20, 1999. The Company
filed a Registration Statement registering the resale of the shares of the
common stock underlying the Series A Stock on July 23, 1999, which was
declared effective by the SEC on September 14, 1999. On the closing date
of the private placement, the conversion price of the Series A Stock was
less than the market price of the common stock, which resulted in a
beneficial conversion of $5 million. The beneficial conversion was
recorded as common stock and was accreted to preferred stock ratably from
the closing date of the preferred stock to August 20, 1999.
F-15
EMPLOYEE STOCK PURCHASE PLAN
Effective October 14, 1998, the Company's Board of Directors approved an
Employee Stock Purchase Plan for qualified employees of the Company. Under
the terms of the Employee Stock Purchase Plan, an employee may purchase up
to $25,000 per calendar year of the Company's stock at a price of 85% of
the fair market value of the stock (as quoted on the NASDAQ national
quotation system) on the date of the purchase. The purchase price is
determined based upon either the first or last day of a calendar quarter.
There have been 500,000 shares of the Company's stock set aside for
purchases to be made under the Employee Stock Purchase Plan. During the
years ended December 31, 1999 and 1998, 518 and 7,575 shares were
purchased under the Employee Stock Purchase Plan at a price of
approximately $1.159 and $0.757, respectively, per share.
NOTE 8 - EMPLOYEE BENEFIT PLAN
In 1988, the Company adopted a profit sharing plan covering substantially
all of its employees. Under the profit sharing plan, the Company may, at
the discretion of the Board of Directors, contribute a portion of the
Company's current or accumulated earnings. In September 1998, the Company
amended and restated the profit sharing plan to include provisions for
Section 401(k) of the Internal Revenue Code. Under the amended and
restated plan, the Company may, at the discretion of the Board of
Directors, "match" a portion of the participant contributions. Company
contributions, if any, are credited to the participant's account and vest
over a period of four years based on the participant's initial service
date with the Company. During the years ended December 31, 1999, 1998, and
1997, no contributions were made to the amended and restated profit
sharing plan or the original profit sharing plan, respectively.
NOTE 9 - STOCK OPTION PLAN
The Company applies SFAS No. 123, "Accounting for Stock-Based
Compensation" (SFAS 123), which defines a fair value based method of
accounting for employee stock options or similar equity instruments and
encourages all entities to adopt that method of accounting for all of
their employee stock compensation plans. Under the fair value based
method, compensation cost is measured at the grant date based on the value
of the award and is recognized over the service period of the award, which
is usually the vesting period. However, SFAS 123 also allows entities to
continue to measure compensation costs for employee stock compensation
plans using the intrinsic value method of accounting prescribed in APB
Opinion No. 25, "Accounting for Stock Issued to Employees" (APB 25). The
Company has elected to remain with the accounting prescribed by APB 25.
The Company has made the required disclosures prescribed by SFAS 123.
In June 1996, the Company's shareholders approved the adoption of the
Medical Science Systems, Inc. 1996 Equity Incentive Plan (the "Plan"). The
Plan provides for the award of nonqualified and incentive stock options,
restricted stock, and stock bonuses to employees, directors, officers, and
consultants of the Company. A total of 1,300,000 shares of the Company's
common stock have been reserved for award under the amended Plan.
Nonqualified and incentive stock options with a life of ten years are
granted at exercise prices equal to the fair market value of the common
stock on the date of grant. Options granted before December 31, 1997, vest
as follows: one-sixth of the options are generally available for exercise
F-16
at the end of six months and the remainder of the grant is exercisable
ratably over the next 30-month period provided the optionee remains in
service to the Company. Options granted after January 1, 1998, vest
ratably over four years after each anniversary date provided the optionee
remains in service to the Company. The Company may also award share
appreciation rights ("SARs") either in tandem with stock options or
independently. At December 31, 1999, 1998, and 1997, no SARs have been
awarded under the Plan.
On October 14, 1998, the Company's Board of Directors voted to reduce the
exercise price for all outstanding options granted under the 1996 Equity
Incentive Plan to one half of the previous price per share, but not to a
price below $1.85 per share. The close of the Company's common stock on
the previous day was $1.25 per share.
Had compensation cost for these options been determined consistent with
SFAS 123, the Company's net loss and net loss per share (EPS) would have
been changed to the following pro forma amounts at December 31:
1999 1998 1997
-------------- -------------- --------------
Net loss
applicable to
common stock ............. As Reported $ (11,138,603) $ (9,508,275) $ (4,494,062)
Pro Forma (12,024,156) (9,855,915) (4,796,791)
EPS ........................ As Reported $ (1.15) $ (1.72) $ (1.19)
Pro Forma (1.24) (1.78) (1.27)
The fair value of each option grant is estimated on the date of grant
using an option pricing model, which approximates the Black-Scholes option
pricing model, for a stock that does not pay dividends with the following
assumptions.
YEARS ENDED DECEMBER 31,
-------------------------------------
1999 1998 1997
--------- --------- ---------
Risk free interest rate .............. 4.7%-6.2% 5.5% 6.4%
Expected life ........................ 7 years 7 years 7 years
Expected volatility .................. 156% 143% 61%
Because the SFAS 123 method of accounting has not been applied to options
granted prior to January 1, 1995, the resulting pro forma compensation
cost may not be representative of that to be expected in future years.
F-17
A summary of the status of the Company's stock options, issued both under
the Plan and outside the Plan, at December 31, 1999, 1998 and 1997, and
changes during the years then ended is presented in the table and
narrative below:
1999 1998 1997
--------------------------- --------------------------- ---------------------------
WEIGHTED WEIGHTED WEIGHTED
AVERAGE AVERAGE AVERAGE
EXERCISE EXERCISE EXERCISE
PRICE PRICE PRICE
SHARES PER SHARE SHARES PER SHARE SHARES PER SHARE
----------- ----------- ----------- ----------- ----------- -----------
Outstanding,
beginning of year 1,174,383 $ 2.20 792,640 $ 4.37 142,500 $ 3.70
Granted ....... 1,061,781 $ 2.05 1,188,783 $ 2.31 659,079 $ 4.46
Exercised ..... (199,314) $ 1.98 -- -- (8,939) $ 4.74
Canceled ...... (314,720) $ 2.15 (807,040) $ 4.37 -- --
----------- ----------- -----------
Outstanding,
end of year ..... 1,722,130 $ 2.11 1,174,383 $ 2.20 792,640 $ 4.37
Options
exercisable, end
of year ......... 889,852 487,502 212,543
Weighted average
fair value of
options granted . $ 2.48 $ 1.39 $ 2.55
The following table summarizes the information about options outstanding
at December 31, 1999:
STOCK OPTIONS OUTSTANDING STOCK OPTIONS EXERCISABLE
----------------------------------- -------------------------
WEIGHTED
AVERAGE NUMBER
REMAINING WEIGHTED EXERCISABLE WEIGHTED
CONTRACTUAL AVERAGE AT AVERAGE
RANGE OF NUMBER LIFE EXERCISE DECEMBER 31, EXERCISE
EXERCISE PRICES OUTSTANDING (YEARS) PRICE 1999 PRICE
- --------------- ----------- ------- --------- ---------- ---------
$.50 - $.99 344,265 9.37 $ .58 132,568 $ .65
$1.00 - $1.49 64,350 8.92 1.25 64,350 1.25
$1.50 - $1.99 286,814 7.34 1.82 274,119 1.82
$2.00 - $2.49 182,800 8.69 2.25 136,767 2.28
$2.50 - $6.00 843,901 9.22 2.86 282,048 2.83
---------- ----------
1,722,130 $ 2.11 889,852 $1.99
========== ==========
The Plan also provides for the award of restricted stock to eligible
persons. Such awards may be at prices not less than 85% of the fair market
value of the Company's common stock as determined by the Board of
Directors. In addition, stock bonuses may be awarded to certain employees
or officers of the Company at the discretion of the Board of Directors. As
of December 31, 1999, the Company has not awarded any restricted stock or
stock bonuses.
F-18
In May 1997, the Company offered to its employees the opportunity to
receive stock options to acquire shares of the Company's common stock at
$5.00 to $5.50 per share in an exchange for a reduction in salary. Certain
employees elected to reduce their salaries up to 100% for the period from
May 1997 to October 1997 in exchange for 600 stock options for each $1,000
of salary reduction. As a result, the Company issued 267,079 stock options
in exchange for salary reductions of $445,132. The Company recorded an
expense relating to the issuance of these stock options in the amount of
$74,189 per month for each of the six months from May 1997 to October
1997.
During 1998, the Company awarded nonqualified stock options to outside
consultants for services rendered. As a result, the Company recognized
$62,000 in selling, general and administrative expense for the issue of
these options. This amount represents the then fair market value of the
services rendered to the Company based on the consultants' usual and
customary charges for the services rendered.
NOTE 10 - COMMITMENTS AND CONTINGENCIES
The Company leases its office space under non cancelable operating leases
expiring through May 2003. In June 1998, the Company consolidated its
corporate offices into its San Antonio Research and Development facility.
As a result of this move, the Company subleased its leased space in
Newport Beach, CA. The sublease expires on the same date of the Company's
lease in April 2001. The sublease income is aggregated with the net rent
expense and included in other income and expense in the Consolidated
Statements of Operations.
The Company also leases certain office furniture and equipment under
capitalized lease obligations. Future minimum rental commitments, net of
sublease income, under lease agreements with initial or remaining terms of
one year or more at December 31, 1999, are as follows:
YEAR ENDING OPERATING CAPITAL
DECEMBER 31 LEASES LEASES
----------- ----------- ----------
2000 $ 80,132 $ 93,216
2001 76,151 63,961
2002 83,995 38,673
2003 35,003 11,174
----------- ----------
$ 275,281 207,024
===========
Less- Amount representing interest 43,901
----------
163,123
Less- Current portion 63,877
----------
Long-term portion $ 99,246
==========
Included in furniture and equipment is capitalized leased equipment of
$377,627 with accumulated depreciation of $225,137 at December 31, 1999.
Rent expense, net of sublease income, was $199,346, $220,587 and $102,815
for the years ended December 31, 1999, 1998 and 1997, respectively.
F-19
EMPLOYMENT AGREEMENTS
The Company entered into employment agreements with certain key employees
of the Company which range from one to five years.
SHEFFIELD UNIVERSITY MASTER AGREEMENT
The Company has entered into an arrangement with Sheffield University (the
Agreement) whereby the Company will undertake the development and
commercialization of certain discoveries resulting from Sheffield
University's research. The Agreement with Sheffield University (the
University) is a five-year agreement with an automatic yearly renewal. In
accordance with the Agreement, the Company issued 275,000 shares of common
stock to the University for past research services, the value of which was
expensed in the third quarter of 1999. Additionally, each year beginning
July 1, 2000, the University will receive 25,000 stock options at the then
current market price, plus 10,000 options for each new patent application
filed in the previous 12 months. These options will be fully vested upon
the grant date and have a five-year exercise period. The Company signed
another agreement with the University for research and development
services which automatically renews in one-year increments. Both
agreements can be canceled if the key collaborator leaves the University.
In September 1999, a five-year Consulting Agreement was entered into with
the University's key collaborator. In accordance with the Consulting
Agreement, the key collaborator received 200,000 shares of common stock
for past research services, the value of which was expensed in the third
quarter. The key collaborator will also receive 1% of the first $4 million
of net sales under the PST Technology and 2% for sales above $4 million.
Payments are required 45 days after each quarter end. Beginning July 1,
2000, in consideration for future services, the key collaborator will
receive 25,000 stock options at the then current market price. These
options have a five-year exercise period from the date of grant.
NOTE 11 - SEGMENT INFORMATION
During 1998, the Company adopted SFAS No. 131, "Disclosures about Segments
of an Enterprise and Related Information." SFAS No. 131 establishes new
standards for reporting information about operating segments in annual and
interim financial statements, requiring that public business enterprises
report financial and descriptive information about its reportable segments
based on a management approach. SFAS No. 131 also establishes standards
for related disclosures about products and services, geographic areas and
major customers. In applying the requirements of this statement, each of
the Company's geographic areas described below were determined to be an
operating segment as defined by the statement, but have been aggregated as
allowed by the statement for reporting purposes. As a result, the Company
continues to have one reportable segment, which is the development of
genetic susceptibility tests and therapeutic targets for common diseases.
F-20
The following table presents information about the Company by geographic
area:
FOR THE YEARS ENDED DECEMBER 31
-----------------------------------------------
1999 1998 1997
----------- ----------- -----------
Total Revenues:
United States ......... $ 281,239 $ 319,145 $ 171,358
France ................ 38,846 23,730 1,370
Other foreign ......... 157,412 70,067 23,200
----------- ----------- -----------
Total ......... $ 477,497 $ 412,942 $ 195,928
=========== =========== ===========
Operating Income:
United States ......... $(3,650,968) $(7,576,319) $(3,552,646)
France ................ (504,288) (563,337) (28,403)
Other foreign ......... (2,043,484) (1,663,350) (480,990)
----------- ----------- -----------
Total ......... $(6,198,740) $(9,803,006) $(4,062,039)
=========== =========== ===========
AS OF DECEMBER 31
------------------------------
1999 1998
---------- ----------
Assets:
United States ....................... $3,176,159 $3,672,890
France .............................. -- --
Other foreign ....................... -- --
---------- ----------
Total ................... $3,176,159 $3,672,890
========== ==========
CONCENTRATIONS OF RISK
The Company sells products and provides contract services for customers
primarily in the United States and France and extends credit based on an
evaluation of the customer's financial condition, generally without
requiring collateral. The Company monitors its exposure for credit losses
and maintains allowances for anticipated losses.
During the year ended December 31, 1999, no one customer accounted for
more than 10% of total revenues. During the year ended December 31, 1999,
the Company obtained lab services for its genetic susceptibility tests
from two companies whose services comprised approximately 30% and 12% of
cost of sales, respectively.
NOTE 12 - SUBSEQUENT EVENTS
In January 2000, the Company sold 832,667 shares of common stock in a
private placement. The Company received net proceeds of approximately $4.7
million from this private placement.
F-21